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ABSTRACT 
 
Sheila L. Flack 
Biological Monitoring of Occupational Exposure to  
Monomeric 1,6-Hexamethylene Diisocyanate 
(Under the direction of Leena A. Nylander-French) 
 
 
   1,6-hexamethylene diisocyanate (HDI) is used throughout the automotive repair industry and is a 
commonly reported cause of occupational asthma in industrialized populations.  However, the exact 
pathological mechanism remains uncertain.  Biomarkers from HDI exposure can fill important 
knowledge gaps between exposure, susceptibility, and the rise of immunological reactions and 
sensitization leading to asthma.   Use of biomarkers in HDI exposure assessment has been limited due 
to the lack of specific and sensitive analytical methods for their measurement.  The objective of this 
research was to develop and apply quantitative methods for the analysis of novel blood and urinary 
biomarkers stemming from exposure to HDI monomer to be utilized in HDI exposure assessment 
studies.  To achieve this, we monitored dermal and inhalation exposure to HDI monomer and 
collected blood and urine from 46 automotive painters.  Analytical methods were developed and 
utilized to quantify 1,6-hexamethylene diamine (HDA) in plasma and hemoglobin and to quantify N-
acetyl-1,6-hexamethylene diamine (monoacetyl-HDA) and N,N’-diacetyl-1,6-hexamethylene diamine 
(diacetyl-HDA) in urine and hemoglobin.  Strong associations between cumulative exposure to HDI 
monomer (dermal or inhalation) and plasma HDA or HDA-hemoglobin adducts were observed (p ≤ 
0.10).  The significant workplace determinants of plasma HDA levels were paint booth type and 
coveralls (p ≤ 0.10).  These biomarkers may be used in HDI exposure assessment to evaluate 
workplace controls for reducing exposures and, thus, prevent adverse health effects among workers. 
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CHAPTER 1 
 
BACKGROUND AND SIGNIFICANCE 
 
 
   The high reactivity of 1,6-hexamethylene diisocyanate (HDI) serves as a basis for producing 
polyurethane-based coatings and is widely used in the automotive refinishing industry.  However, 
exposure to these compounds can present health risks in the workplace.  Measurement of HDI in the 
air alone is insufficient for exposure assessment as individual differences in breathing rate, 
deposition, absorption, distribution, and metabolism are not taken into account.  Furthermore, the 
mechanisms of toxic reactions and information on exposure routes and their contribution to internal 
dose levels have not yet been adequately addressed in HDI exposure assessment.  Utilizing 
biomarkers in HDI exposure assessment would improve our understanding of mechanisms and 
susceptibility factors involved in diisocyanate-induced asthma and help establish exposure mitigation 
controls in the workplace.  In this chapter, I describe the current knowledge of HDI metabolism, 
proposed mechanisms involved in diisocyanate-induced asthma, methods used in biomonitoring of 
HDI exposure, and the specific aims of this project. 
 
1.1 Health effects of exposure to HDI 
   HDI (see Figure 1.1: 1
a
) is the most commonly used aliphatic diisocyanate for the production of 
polyurethane foams and coatings
1
.  Its highly reactive isocyanato (NCO) moieties react readily with 
the hydroxyl (OH) group of polyols to form polyurethanes, and hence have been utilized in the 
automotive repair industry as a component of polyurethane paints and coatings.  Painting air levels 
                                                 
a
 Numbers and letters in bold (e.g., 1, 1A) refer to the specific chemical reaction product and protein adducts, 
respectively, in Figure 1. 
 
2 
 
typically consist of trace amounts of HDI monomer and larger amounts of HDI oligomers (e.g., 
uretdione, biuret, and isocyanurate)
2, 3
.  However, skin sensitization produced at these trace levels to 
HDI monomer (0.1%) is sufficient to induce HDI-induced asthma following inhalation exposure
4
.  
Therefore, characterizing and quantifying biomarkers of HDI monomer exposure continues to be 
critical in evaluating workplace exposure, developing strategies for mitigating exposure, and 
preventing adverse health effects.  In this section, we review our current understanding of health 
effects associated with HDI exposure, metabolism, mechanisms, and risk factors involved in 
diisocyanate-induced asthma. 
 
1.1.1 Overview of health effects 
   Isocyanate-induced asthma is the major health problem associated with exposure to HDI, and has 
been documented among occupationally exposed workers
5-8
.  Other effects resulting from HDI 
exposure include allergic rhinitis, hypersensitivity pneumonitis, and contact dermatitis
9, 10
.  A 
diisocyanate-exposed worker may become sensitized after a single, acute exposure, but in most cases, 
sensitization takes months to several years of exposure
11
.  Additionally, once a worker is sensitized, 
s/he can experience an asthmatic response when exposed to inhalation levels below the occupational 
exposure limit
12
.  This response is characterized by an early asthmatic reaction and rapid recovery 
period, followed by a prolonged decline in lung function
5
.  There is evidence that inducing HDI skin 
sensitization at trace levels of HDI monomer (0.1%) with subsequent inhalation challenge may result 
in lung and airway inflammation, characterized by a mixed Th1/Th2 immune response
4
.  The low 
prevalence (5 – 10%) of diisocyanate-induced asthma among exposed individuals and HDI-specific 
IgE among asthma cases
13-15
 has generated interest in understanding the role of genetic factors driving 
HDI metabolism as modifiers of individual susceptibility to asthma
16
.    
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1.1.2 Metabolism of HDI 
   Several non-enzymatic and enzymatic-directed metabolic pathways have been identified following 
HDI exposure, which are summarized Figure 1.1.  Once absorbed into the body, the NCO moieties of 
HDI react with protein functional groups such as amines, hydroxyls, and thiols, with the last of these 
reactions favored under physiologic conditions
17
.  HDI reacts spontaneously, or through catalysis by 
glutathione-S-transferase (GST), with thiol groups in cysteine residues of glutathione (GSH) and 
other proteins to form mono- and bis-dithiocarbamate adducts (see Figure 1.1: 2)
17, 18
.  In vitro studies 
indicated that HDI-protein conjugates are also created via the base-catalyzed elimination reaction of 
the bis-dithiocarbamate adducts (2) to form an intermediate S-glutathionyl adduct (3), which can 
undergo carbamoylation reactions with proteins or undergo solvolysis to regenerate HDI (1), resulting 
in potential carbamoylations with other nucleophilic sites on albumin or hemoglobin far from the 
initial site of contact (2A).  This reaction pathway competes with the base-catalyzed biomolecular 
substitution reaction, leading to the formation of the very labile carbamic acid group (4), which 
decomposes to HDA (5)
18
.  Because these reaction pathways were demonstrated in vitro, it is still 
unknown whether these metabolic products are formed in humans following occupational exposure to 
HDI.   
   Sepai and colleagues (1995) proposed an alternative pathway for diisocyanate-adduct formation 
based on measurements of 4,4’-methylenedianiline (MDA) and N’-acetyl-4,4’-methylenedianiline 
(monoacetyl-MDA) in blood and urine samples
19
.  This proposed metabolic pathway for HDI is based 
on the N-hydroxylation of the amines (5, 6), catalyzed by cytochrome P-450 isoforms (CYP450) or 
flavine-adenine dinucleotide (FAD) dependent enzyme system (e.g., flavine-containing 
monooxygenase)
20
, resulting in the formation of N-hydroxyamine (8) and the nitroso compound (9), 
which can react with thiols on albumin or hemoglobin (3A).  This pathway competes with N-
acetylation of the amine, catalyzed by N-acetyltransferase (NAT) enzymes, to form monoacetylated 
(6) and diacetylated amines (7), which are excreted in urine.  The identification of N-acetyl-1,6-
hexamethylene diamine (monoacetyl-HDA) in individuals receiving HDA by oral administration also 
4 
 
indicates the potential for this metabolic pathway
21
.  However, N-acetylation following occupational 
exposure to HDI, where dermal and inhalation are the major exposure routes, has not been 
established.   How HDI is transformed in vivo may have important implications in exposure 
assessment, the biological availability of different reactive intermediates, as well as the development 
of adverse health effects.
 
Figure 1.1 Proposed enzymatic (GST, NAT, CYP450, FAD) and non-enzymatic directed HDI metabolic pathways leading to formation 
of HDI-protein adducts, potential immune response, and elimination. 
5
 
 HN 
6 
 
1.1.3 Mechanisms of diisocyanate-induced asthma 
 
   While the biological mechanisms by which diisocyanates cause asthma remain poorly understood, 
the low proportion of diisocyanate-induced asthmatics with detectable specific IgE
7, 14
 has generated 
theories concerning disease mechanisms and genetic susceptibility.  Unlike high molecular weight 
allergens, diisocyanates may react with amino, hydroxyl, and sulfhydryl groups of various proteins 
and peptides, including albumin and keratin, to form hapten-protein complexes
22
.  Cell-mediated 
mechanisms would enable these proteins to act as hapten-carriers (i.e., antigen presenting cells) in 
presenting HDI to the immune system (see Figure 1.1: 1A), resulting in induction of a mixed Th1/Th2 
type response, lymphocyte production
4, 23-25
, and peripheral blood mononuclear cell responses, which 
has been demonstrated in human subjects receiving inhalation exposure to HDI-albumin conjugate
26
 
(Figure 1.1).   Analogously, allergen-induced delayed dermatitis (or type IV hypersensitivity) occurs 
when sensitizing chemicals penetrate the viable epidermis and stimulate IgG/IgE production and T-
cell response.  Langerhan’s cells can transport HDI as a hapten-carrier complex from the skin to the 
lymph nodes, where it is presented to naïve T-cells with subsequent transformation into memory T-
cells (i.e., sensitization phase).  With subsequent exposure, memory T-cells would travel to the site of 
exposure and produce inflammation and systemic immune response (i.e., elicitation phase).  A similar 
class of hapten-carrier complexes (e.g., HDI-conjugated keratins) formed following skin and airway 
exposure to HDI may explain cases of asthmatic response elicited by inhalation challenge in guinea 
pigs or mice sensitized previously by dermal exposure to diisocyanates
4, 23, 27
. 
   Hereditary factors may also work in conjunction with cell-mediated mechanisms to modify 
individual susceptibility to diisocyanate-induced asthma.  Cysteinyl leukotrienes are potent mediators 
of airway narrowing and have been implicated as possible mediators of hyperresponsiveness to 
histamine, which is a key feature in bronchial asthma
28
.  GSTs can utilize a variety of pro-
inflammatory leukotrienes as substrates, and exhibit polymorphic expression due to their allelic 
variants in the respective genes
16
.  Genetic polymorphisms of GSTs may modify asthmatic responses 
to diisocyanate exposure through detoxification of diisocyanates or their metabolites, acting as pro-
7 
 
inflammatory mediators in airway reaction to diisocyanates, or toxicity via GSH-protein conjugates 
which could lead to the formation of hapten complexes giving rise to immunological reactions.  
Similarly, large inter-individual variability in NAT enzyme activities exists due to polymorphisms in 
NAT1 and NAT2 genes.  Therefore, NATs are another group of enzymes whose genetic 
polymorphisms may modify the development of adverse effects due to diisocyanate exposure.  The N-
acetylation pathway competes with N-hydroxylation, which is a metabolic activation route leading to 
the formation of N-hydroxyamine and the nitroso compound capable of binding covalently to 
molecules.  Thus, hapten formation, and consequently asthma risk, would be predicted to be enhanced 
in humans with slow acetylator phenotype compared to fast acetylator phenotype.  In support of this 
hypothesis, Wikman and colleagues (2002) demonstrated that the largest increase in asthma risk was 
observed with the combined GSTM1 null genotype and the NAT1 slow acetylator phenotype (OR = 
4.5)
16
.  Additionally, Brorson and colleagues (1990) found that individuals with the NAT slow 
acetylator phenotype cleared lower amounts of HDA following oral administration of HDA compared 
to individuals with fast acetylator phenotype, indicating modification of hapten formation with 
acetylator status
21
.  Further investigation into factors driving HDI metabolism and clearance 
following occupational exposure to HDI would contribute to our understanding of mechanisms and 
susceptibility factors involved in diisocyanate-induced asthma. 
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1.2 Automotive refinishing industry 
   Auto body shop painters and repair technicians use polyurethane paints containing HDI for spray 
and refinishing work.  The auto body industry in the U.S. employs >205,000 workers in ~35,500 auto 
body shops (U.S. Bureau of Census, 2002).  Spray painters have been reported to be the highest risk 
group for developing occupational asthma compared to other occupations
29
.  Therefore, 
characterizing occupational exposure to HDI is important for establishing and improving protection 
controls and mitigating disease.  In this section, I describe the painting process in the automotive 
refinishing industry and methods involved in exposure monitoring. 
 
1.2.1 Painting process and HDI exposure 
   Paints used in the automotive refinishing industry contain aliphatic diisocyanates, consisting of 
trace amounts of HDI monomer (< 1%) and much higher amounts of HDI oligomers
30, 31
, including 
the dimer, uretidone, and trimers, biuret and isocyanurate.  Paints are applied using a two-stage 
system in which the first stage is the base coat, and the second stage is the clearcoat to which 
hardener, containing monomeric and polymeric HDI, is added.  Once mixed, the polyisocyanates in 
the hardener react with the polyols in the clearcoat solution to form a polyurethane coating.  
Automotive painting is performed using a compressed-air spray gun inside a ventilated paint booth 
(i.e., downdraft, crossdraft, or semi-downdraft).  Some of the paint droplets may be captured in the 
airflow around the surface of the vehicle, forming a mist or overspray that is likely to contain 
unreacted polyisocyanates
32
 and come into the workers’ personal space.  Therefore, dermal and 
inhalation exposure to HDI are potential exposure routes in this occupation.  To reduce exposure risk, 
the most common types of personal protective equipment (PPE) used during spray painting include 
respirators (e.g., half-face or full-face air purifying, powered-air purifying (PAPR), and supplied air), 
coveralls, and gloves. 
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1.2.2 Methods for dermal and inhalation exposure monitoring 
   Inhalation exposure to HDI most likely occurs during spray-painting when the paint is aerosolized 
and enters the breathing-zone of the worker.  Dermal exposure to HDI may occur during spray-
painting as the aerosol is deposited on the skin or the vapor is absorbed through the skin, contact with 
contaminated or freshly painted surfaces, or directly with the paint containing HDI.  The extent of 
inhalation or dermal exposure depends on the use and efficiency of PPE.  While spray painters 
typically wear a respirator, coveralls and gloves are worn less frequently
33
.  Even when PPE is worn, 
HDI may break through latex gloves or respirator cartridges with repeated use
34
.  Air-purifying 
respirators that implement filtration for reducing inhalation exposure may not sufficiently remove 
diisocyanate aerosols, particularly if workers do not follow routine change-out of filters
35
.  Improper 
maintenance of coveralls or inadequate changing of gloves could also result in dermal exposure to 
HDI. 
   Because HDI oligomers likely exist as aerosols in the overspray while HDI monomer, with its 
higher vapor pressure (0.05 mmHg at 25°C) may partially exist as a vapor, methods to accurately 
measure these compounds present challenges.  Due to their reactivity with water, alcohols, and 
amines, most air sampling methods require immediate derivatization of collected diisocyanates.  
Filter sampling, using single-stage or dual-stage cassettes, are the most commonly used methods for 
collecting diisocyanates in the air.  In a dual-stage system, the first stage consists of a 
polytetrafluoroethylene (PTFE) filter designed to collect aerosols and the second stage contains an 
impregnated glass fiber filter (GFF) designed to collect and derivatize vapor (ISO-CHECK®).  After 
sampling, the PTFE filter is placed into derivatizing solution.  The single-stage system lacks the 
PTFE filter, and consequently, the impregnated GFF collects and derivatizes all phases of the 
diisocyanates (OSHA 1983)
36
. 
   HDI dermal exposure assessment is much less developed than that of inhalation exposure 
22
, 
although the role of dermal exposure in sensitization and diisocyanate-induced asthma has been 
demonstrated
27, 37
.  Several different techniques have been used to detect and/or quantify these levels 
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in the workplace including SWYPE pads
34
, wipes
38
, glove washes
39
, and tape-strips
40, 41
.  The lack of 
a standardized and fully validated method to assess HDI dermal exposure has added to the difficulty 
in characterizing dermal exposure.  Evidence that dermal exposure occurs among automotive spray 
painters stresses the need to validate methods to measure skin exposure
34, 38, 39, 41
.  Post-exposure tape-
stripping of the skin has the advantage of quantifying dermal penetration of HDI monomer and 
oligomers within the same sample 
41
 and the potential to be adapted to collect and measure HDI-
keratin adducts that have been identified in vivo
23
. 
 
1.3 Biological monitoring of exposure to HDI 
   Measures of exposure levels alone, through tape-stripping of the skin or air monitoring, are 
insufficient to fully understand mechanisms involved in sensitization.  Information on HDI 
metabolism and protein adduct formation following diisocyanate exposure has contributed to our 
understanding of the possible mechanisms involved in sensitization and development of diisocyanate-
induced asthma
23, 24, 42
.  Biological monitoring, through measurement of one or more internal markers 
in the blood or urine, can be combined with HDI exposure and disease monitoring to understand 
workplace and personal factors including susceptibility that modify exposure and asthma risk, 
respectively.  The integration of biological monitoring (i.e., internal dose of a chemical or its 
metabolites) within the source-disease framework for HDI is summarized in Figure 1.2.  The internal 
dose resulting from HDI exposure can be related with both HDI exposure and the target organ dose, 
which may continue towards disease progression and produce HDI-induced asthma.  In this section, I 
describe the methodology used in biological monitoring of exposure to HDI, including blood and 
urine analysis, and their relationship with HDI exposure levels. 
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Figure 1.2 Source to disease framework for HDI exposure. 
 
1.3.1 Analytical methods for biomarker quantification (sensitivity and specificity) 
 
   Biological monitoring of HDI exposure has primarily involved analysis of HDA, the hydrolysis 
product of HDI, in urine or plasma as a marker of exposure to HDI.  Typically, 1-2 ml of urine or 
plasma is hydrolyzed by acid or base, and the liberated diamines are extracted into toluene followed 
by derivatization with heptafluorobutyric anhydride (HFBA) or pentafluoropropionic anhydride 
(PFPA) and analyzed by gas chromatography-mass spectrometry (GC-MS) in negative chemical 
ionization mode
43, 44
 or by liquid chromatography-mass spectrometry (LC-MS)
45
.  The former has 
been the most commonly used method for HDA analysis and implemented primarily when HFBA 
was used as the derivatization agent.  The detection limits for HDA in plasma or urine as reported in 
various publications are in the range of 0.02 – 3.0 µg/l (summarized in Table 1.1).  The high detection 
limit of HDA in samples, resulting in low analytical sensitivity, has hindered quantification of plasma 
HDA in several studies
43, 46
. 
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Table 1.1 Summary of analytical method and HDA detection limits (µg/l) in biological media. 
Reference Biological media 
Derivatization 
agent
a
 
Analytical 
method
b
 
Detection 
limit (µg/l) 
Brorson et al. 1990
43
 plasma & urine HFBA  GC-MS 0.5 
Dalene et al. 1994
44
 urine TFECF GC-MS 0.5 
Skarping et al. 1994
45
 urine PFPA LC-MS 0.1 
Tinnerberg et al. 1995
46
 plasma & urine PFPA GC-MS ≤0.1 
Maitre et al. 1996
47
 urine HFBA  GC-MS 0.35 
Rosenberg et al. 2002
48
 urine HFBA  GC-MS 0.4
c
 
Liu et al. 2004
49
 urine HFBA  GC-MS 0.2 
Pronk et al. 2006
39
 urine HFBA GC-MS 3.0 
Gaines et al. 2009
50
 urine HFBA  GC-MS 0.04 
Flack et al. 2009
51
 plasma HFBA  GC-MS 0.02 
a.
 HFBA = heptafluorobutyric anhydride; TFECF = 2’,2’,2-trifluoroethyl chloroformate; PFPA = 
pentafluoropropionic anhydride. 
b.
 GC-MS = gas chromatography-mass spectrometry; LC-MS = liquid chromatography-mass spectrometry. 
c.
 Reported as limit of quantification (LOQ) = 5 nmol/l = limit of detection (LOD) × 1.5 
48
, and LOD (µg/l) 
calculated as follows:  5 nmol/l ÷ 1.5 × 1 mol/10
9
 nmol × 116.21 g/mol × 10
6
 µg/g = 0.4 µg/l. 
 
   Acid hydrolysis releases HDA-protein conjugates from biological matrixes and converts the acetyl 
functional groups on monoacetyl-HDA and N,N’-diacetyl-1,6-hexamethylene diamine (diacetyl-
HDA) back to HDA.  Thus, the HDA detected following these treatment conditions may be derived 
from a number of other metabolites and adducts, and any individual variability in specific metabolite 
formation would be masked by acid hydrolysis.  Therefore, analytical specificity for HDI exposure 
biomarkers must be further developed to determine individual differences in specific metabolite 
formation related to HDI monomer and oligomer exposure.  This information would be used to 
understand individual differences in metabolism of HDI and susceptibility factors related to disease 
development. 
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1.3.2 Urine analysis for HDA 
   Positive associations between HDI inhalation exposure and urinary HDA levels have been observed 
in several studies
39, 43, 46, 47, 49
.  Automotive repair workers may be exposed to HDI monomer and 
oligomers simultaneously, complicating methods for biological monitoring of HDI exposure.  
However, Liu and colleagues (2004) demonstrated that the correlation between inhalation exposure to 
biuret and urinary HDA was weak, indicating that HDA levels better reflect HDI monomer exposure 
rather than oligomers
49
.  In addition, knowledge on oligomer metabolism and their association with 
external exposures is lacking, thereby making HDA the only valid biomarker for HDI monomer to 
date. 
   Unlike inhalation exposure, the impact of dermal exposure on urine HDA levels has been 
quantitatively investigated in only one study
50
.  Investigation of these associations between exposure 
and biomarker levels has been hindered not only by the sensitivity of analytical methods, but also by 
the large inter- and intra-individual variability in HDA urine biomarker levels
39
.  In urine, this is 
partially attributed to the biphasic elimination pattern of HDA, characterized by a rapid elimination 
phase (t1/2 = 1.2 – 2.9 h) and a slow elimination phase, which may be attributed to the breakdown of 
HDI-protein conjugates in the blood
43, 46, 49
.  Furthermore, analyses of HDA in acid hydrolyzed urine 
may represent a combination of various metabolites, including free and protein conjugates of HDA 
and acetylated HDA.  Therefore, the quantification of specific HDI metabolites, such as monoacetyl-
HDA or diacetyl-HDA, would improve biological monitoring methods for HDI exposure by reducing 
the inter- and intra-individual variability in biomarker measures and providing further information on 
HDI metabolism.  The association between exposure and internal dose may be investigated to 
evaluate the effectiveness of PPE and other workplace factors in mitigating HDI exposure.  Modifiers 
of HDI metabolism, such as hereditary factors, may also be integrated with these internal dose 
measures to understand individual susceptibility for asthma development. 
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1.3.3 Blood analysis for HDA 
   Similar to urine HDA, measurement of HDA in blood may also be used in evaluating the 
effectiveness of PPE for mitigating exposure, as well as investigating individual susceptibility in 
disease development.  As mentioned previously, if hapten-carrier complexes are important in immune 
response, then measures of blood protein adducts resulting from HDI exposure may be directly 
related with asthma risk.  There are no publications reporting the amount of free or protein-
conjugated HDA in the blood after exposure to HDI monomer.  However, for other diisocyanates it 
has been reported that the majority of MDA measured in the plasma of workers exposed to methylene 
diphenyl diisocyanate (MDI) is covalently bound to albumin, and these levels are up to 450-fold 
higher than hemoglobin (Hb) adduct levels
19
.  Assuming that modified proteins are stable, albumin or 
Hb adducts accumulating in blood may be indicative of cumulative diisocyanate exposure and the 
biological availability of different reactive intermediates over the half-life of albumin (19 days) and 
the life-span of Hb (120 days).  The association between 2,6-toluene diamine (TDA) in hydrolyzed 
urine and airborne levels of toluene diisocyanate (TDI) were more strongly correlated compared to 
plasma TDA levels, perhaps due to the presence of these longer-lived TDA-albumin adducts
52
.  Thus, 
HDA blood biomarkers (e.g., HDA-albumin or HDA-Hb adducts) may also be used to evaluate HDI 
exposures in retrospective studies, where actual exposure measurements are missing. 
 
1.4 Modeling the exposure-biomarker relationship 
   Predictive models describing the relationship between HDI exposure and biomarkers can be used to 
identify the major routes of exposure, as well as workplace and individual-level covariates that may 
modify these relationships, such as PPE and engineering controls in the workplace.  The inter-
individual variability in HDI metabolism may also be investigated to understand susceptibility 
factors, such as NAT and GST gene polymorphisms, associated with disease risk.  In this section, we 
describe how HDI exposure and biomarker levels, modified by PPE and workplace factors, may be 
associated using statistical modeling. 
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1.4.1 Internal dose modeling 
   Linear regression models have demonstrated good associations (r ≥ 0.49) between HDI air exposure 
and post-shift urinary HDA
47, 49
 indicating that urine HDA is a useful marker of short-term HDI 
exposure.  Logistic regression has also been used to investigate the association between urine HDA 
levels, external dermal exposure, and glove use, with odds ratios (ORs) adjusted for correlation 
among repeated measures
39
.  The limitation in the latter study was implementing glove washes to 
estimate dermal exposure rather than direct quantitative measures of the skin exposure, as glove type 
(e.g., nitrile vs. latex) may affect the extent of dermal exposure to the hands.  Additionally, 
differences in respiration rate, HDI uptake, absorption, metabolism (e.g., acetylator status), and HDI-
conjugate clearance rates would contribute to the large inter-individual variability in urinary HDA 
levels observed in these studies.   
   Mixed modeling has been implemented for identifying the main determinants of dermal and 
breathing-zone HDI monomer and oligomers
41, 53
.  Such models could also be implemented to 
identify the main determinants of biomarker concentration resulting from HDI exposure using 
repeated measures.  Mixed models are statistical models that incorporate both fixed and random 
effects in making predictions of the dependant variable (e.g., biomarker concentration).  They are 
useful in settings where repeated measures are made on the same statistical units (e.g., worker).  Due 
to the likelihood of serial correlation with repeated measures, the mixed model approach would be an 
appropriate method for biological samples.   
   The general form of the linear mixed model investigating the association of exposure concentration 
and personal or workplace covariates on biomarker concentration is: 
Yij = 0 + 1X1ij + 2X2ij + i + ij, 
where Yij represents the log-transformed biomarker concentration (the jth measurement obtained for 
the ith worker), X1ij represents the log-transformed exposure concentration (e.g., inhalation exposure), 
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X2ij represents the covariate being tested (e.g., coverall use), 1 and  2 represent regression 
coefficients of the explanatory variables, 0 represents the intercept, and i and ij represent the 
random effects associated with worker (i for i = 1, 2,..., n workers) and an error term (ij for j = 1, 2,. 
. ., N measurements for the ith worker).  It is assumed that i and ij are mutually independent and 
normally distributed with means of zero and respective variances σ2b and σ
2
w representing the 
between and within-worker variance components, where total variance σ2Y = σ
2
w + σ
2
b.  It is also 
assumed that Yij is normally distributed with mean µy = 0 + 1X1ij + 2X2ij and variance σ
2
Y.   
   These statistical models may be used to evaluate the association between exposure and biomarker 
concentrations, and how personal and workplace covariates, such as PPE use, modify these 
associations and biomarker concentration.  Identifying sources of the between and within-worker 
variability in biomarker measurements would help establish workplace and personal protection 
strategies in mitigating exposure and disease. 
   Another useful statistical analysis is the Tukey-Kramer multiple comparison test (Tukey’s test) 
which is used to identify which means, among groups of measurements, are different from each other.  
Thus, it compares all possible pairs of means, and is based on a studentized range distribution q.  
Tukey's test is essentially a t-test, except that it corrects for experiment-wise error rate; when there are 
multiple comparisons being made, the probability of making a type I error increases. Tukey's test 
corrects for type I error, and is thus more suitable for multiple comparisons than perfoming a number 
of t-tests.  Additionally, for unequal sample sizes, the confidence coefficient is greater than 1 – α.  
Therefore, Tukey’s test is more conservative when dealing with unequal sample sizes. 
The general formula for Tukey’s test is:   
where YA is the larger of the two means being compared, and YB is the smaller of the two means 
being compared and SE is the standard error of the data in question.  This qs value can then be 
compared to a q value from the studentized range distribution (qcritical). If the qs value is larger than the 
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qcritical value obtained from the distribution, the two means are significantly different.  In exposure 
assessment, this test may be used to compare the means in biomarker levels (e.g., plasma HDA, 
HDA-Hb) when workers are grouped by PPE use (e.g., coverall use vs. non-coverall use). 
 
1.4.2 Retrospective HDI exposure assessment 
   Several studies have indicated both fast and slow transformation and elimination of HDI in the 
human body, with the possibility of the latter phase comprised of the breakdown and release of 
protein adducts, such as HDA-albumin and HDA-Hb adducts
43, 46, 49
.  Therefore, exposure-biomarker 
associations should also aim to investigate the relationship between biomarker and retrospective HDI 
exposure occurring over a range of time spanning the life-span of Hb (120 days) and, at minimum, the 
half-life of albumin (19 days).  The strong association between urinary HDA and the same day HDI 
exposure was attributed to the rapid elimination of HDI
47, 49
.  However, the measurement of blood-
protein adducts may be applied in retrospective HDI exposure assessment studies where exposure 
measures are missing.  How long these adducts remain in circulation may reflect the biological 
availability of these products over this time period and their potential contribution to sensitization and 
asthma.  Thus, HDA-albumin and HDA-Hb adducts and urine HDA levels may be utilized as 
biomarkers of HDI exposure occurring at various times (i.e., same day, 0.5 – 2 months, 0.5 – 4 
months) relative to the collection of the biological sample. 
 
1.5 Specific aims of this project 
   The primary objective of this project was to develop and apply quantitative methods for the analysis 
of novel blood and urinary biomarkers stemming from exposure to HDI monomer.  This investigation 
was conducted to identify the most significant personal and workplace determinants for estimating the 
received internal dose and evaluate the effectiveness of PPE and other workplace controls in 
mitigating exposure.  To achieve our primary objective we identified the following specific aims: 
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Specific Aim 1:  Quantify HDA in plasma of workers exposed to HDI monomer, investigate their 
relationship with HDI dermal and inhalation exposure levels, and identify the major determinants for 
plasma HDA levels among the various workplace covariates (e.g., coveralls, respirator type, booth 
type). 
Specific Aim 2:  Develop and apply quantitative methods for the analysis of monoacetyl-HDA and 
diacetyl-HDA in the urine of workers exposed to HDI monomer and investigate their relationship 
with HDI dermal and inhalation exposure levels. 
Specific Aim 3:  Quantify hemoglobin adducts of HDA, monoacetyl-HDA, and diacetyl-HDA in 
workers exposed to HDI monomer and investigate their relationship with HDI dermal and inhalation 
exposure levels, urine HDA concentration, and various workplace covariates.
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2.1 Abstract 
   Quantification of amines in biological samples is important for evaluating occupational exposure to 
diisocyanates.  In this study, we describe the quantification of 1,6-hexamethylene diamine (HDA) 
levels in hydrolyzed plasma of 46 spray painters applying HDI-containing paint in vehicle repair 
shops collected during repeated visits to their workplace and their relationship with dermal and 
inhalation exposure to 1,6-hexamethylene diisocyanate (HDI) monomer.  HDA was detected in 76% 
of plasma samples, as heptafluorobutyryl derivatives, and the range of HDA concentrations was 
≤0.02 – 0.92 µg/l.  After log-transformation of the data, the correlation between plasma HDA levels 
and HDI inhalation exposure measured on the same workday was low (N = 108, r = 0.22, p = 0.026) 
compared with the correlation between plasma HDA levels and inhalation exposure occurring 
approximately 20 – 60 days before blood collection (N = 29, r = 0.57, p = 0.0014).  In addition, the 
correlation between plasma HDA levels and HDI dermal exposure measured on the same workday 
was also low (N = 108, r = 0.22, p = 0.040).  We evaluated various workplace factors and controls 
(i.e., location, personal protective equipment use, paint booth type) as modifiers of plasma HDA 
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levels.  Workers using a downdraft-ventilated booth had significantly lower plasma HDA levels 
relative to semi-downdraft and crossdraft booth types (p = 0.0108); this trend was comparable to HDI 
inhalation and dermal exposure levels stratified by booth type.  These findings indicate that HDA 
concentration in hydrolyzed plasma may be used as a biomarker of cumulative inhalation exposure to 
HDI and for investigating the effectiveness of exposure controls in the workplace. 
 
2.2 Introduction 
   The high reactivity of 1,6-hexamethylene diisocyanate (HDI) serves as a basis for producing 
polyurethane-based coatings and is widely used in the auto-repair industry. The reactive nature of 
HDI has also resulted in cases of skin and respiratory sensitization, and occupational asthma with 
repeated or prolonged exposure
5-7, 54
.  However, the mechanisms of toxic reactions and information on 
exposure routes and their contribution to internal dose levels have not yet been adequately addressed 
in HDI exposure assessment.  Evidence that inducing HDI skin sensitization, with subsequent 
inhalation challenge, can result in HDI-induced asthma stresses the importance of investigating 
dermal exposure to HDI and its relationship with internal dose levels
4
.  Therefore, efficiency of 
personal protective equipment (e.g., respirators and coveralls) and routes of exposure (e.g., dermal 
and inhalation) are important considerations in exposure assessment. 
   Biomonitoring may supplement traditional air monitoring methods, or used in combination with 
dermal exposure methods, by integrating previous exposures across multiple exposure routes.  Thus, 
biomarker analysis may be used to evaluate the effectiveness of protection controls in the workplace 
through internal dose estimation of a particular compound.  In addition, HDI-conjugated proteins in 
the blood may contribute to the pathogenesis of diisocyanate-induced asthma by acting as protein 
carriers that present HDI to the immune system as hapten-protein complexes
23
.  Therefore, HDA 
blood biomarkers may provide a link between exposure and the relevant pathways contributing to the 
development of biological effect(s).  Not only may blood biomarkers of HDI exposure be used to 
evaluate the effectiveness of workplace protection controls, but also to investigate biological factors 
21 
 
contributing to disease development.  Investigating how internal dose varies with external exposure to 
HDI monomer may be performed by utilizing a sensitive method for the measurement of HDA in the 
hydrolyzed plasma, and correlating these levels with HDI monomer measured in a worker’s 
breathing-zone and skin. 
   The high reactivity and toxicity of diisocyanates has generated interest in measuring the internal 
dose of these compounds through analysis of one or more biomarkers.  Diisocyanate protein adducts 
form as a result of conjugation of diisocyanates to various macromolecules at the site of contact or 
after systemic absorption
9
.  Albumin or hemoglobin (Hb) adducts in the blood resulting from 
diisocyanate exposure have been identified
19, 55, 56
 and may result from direct interaction with blood 
proteins, or through rapid hydrolysis to the corresponding diamine in the blood, catalyzed by 
bicarbonate
57
, subsequent conversion to the N-acetylated diamine by N-acetyltransferase, and/or 
further hydroxylation catalyzed by cytochrome P450 1A2 leading to the formation of protein 
adducts
16
.  The latter pathway is supported by Sepai and colleagues
19
 who quantified N-acetylated 
hemoglobin adducts resulting from MDI exposure indicating that the isocyanate group may be first 
hydrolyzed to the amine in vivo, followed by N-acetylation to monacetylated MDA, N-hydroxylation 
to the N-hydroxyarylamine and subsequently to the nitroso compound, which can then form a 
sulphinamide adduct.  Therefore, HDA measured from hydrolyzed plasma samples may represent a 
combination of unconjugated HDA and monoacetyl-HDA or diacetyl-HDA, as well as conjugated 
protein adducts of HDI and HDA or monoacetyl-HDA hydroxylation products. 
   There are no publications reporting the amount of free or protein-conjugated HDA in the blood after 
exposure to HDI monomer.  However, for other diisocyanates it has been reported that the majority of 
MDA measured in the plasma of workers exposed to MDI is covalently bound to albumin and these 
levels are up to 450-fold higher than Hb adduct levels
19
.  Assuming that modified proteins are stable, 
albumin or Hb adducts accumulating in blood may be indicative of cumulative diisocyanate exposure 
and biological availability of different reactive intermediates over the half-life of albumin (3 weeks) 
and life span of Hb (17 weeks).  The association between 2,6-toluene diamine (TDA) in hydrolyzed 
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urine and airborne levels of toluene diisocyanate (TDI) were more strongly correlated compared to 
plasma TDA levels, perhaps due to the longer half-life of TDA in plasma (21 days) resulting from the 
formation of albumin adducts
52
.  Thus, HDA blood biomarkers may also be used to evaluate 
exposures in retrospective studies, where actual exposure measurements are missing. 
   Blood or urinary biomarkers may be utilized in exposure assessment by investigating how these 
measures relate to external exposure levels.  Automotive repair workers may be exposed to HDI 
monomer and/or oligomers (e.g., biuret, isocyanurate), with the latter comprising the majority of HDI 
in the clear coat.  While a test chamber exposure study by Liu and colleagues
49
 measured HDA in 
urine of persons exposed to biuret aerosol, the correlation between inhalation exposure to biuret and 
HDA was weak, indicating that HDA may better reflect HDI monomer exposure rather than 
oligomers.  In addition, knowledge on oligomer metabolism and their association with external 
exposures is lacking, thereby making HDA the only valid biomarker for HDI monomer to date. 
   While HDA blood levels were observed to be below the limit of detection (<0.1 µg/l) in two 
previous human exposure studies
43, 46
, a few volunteer and occupational exposure studies have 
demonstrated a positive association between HDI inhalation exposure and measured HDA in 
hydrolyzed urine
46, 47
.  However, due to the large inter- and intra-person variability in urinary HDA 
levels among automotive repair workers and its biphasic elimination pattern, these measures are not 
easily interpretable as markers of HDI exposure
39
.  For other diisocyanates, associations between 
biomarker levels in plasma or urine and diisocyanate air exposure levels have been investigated, 
although the relationship between dermal exposure and internal dose has not been investigated 
adequately.  Strong, positive correlations were found between airborne TDI levels and TDA 
concentrations in hydrolyzed plasma and urine
52, 58
, whereas the association between airborne MDI 
levels and MDA concentrations in hydrolyzed plasma or urine were much weaker
59, 60
, indicating the 
possible contribution of dermal uptake for MDI.  Because quantitative plasma HDA levels among 
exposed workers is lacking, we present a sensitive method for HDA analysis and investigate the 
association between plasma HDA and HDI inhalation and dermal exposure levels. 
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   The contribution of dermal exposure to diisocyanates in sensitization and development of 
diisocyanate-induced asthma has been demonstrated in several animal studies
27, 37
.  The issue of 
dermal absorption of diisocyanates in the occupational setting has been raised by several authors who 
have speculated that dermal exposure may contribute significantly to internal dose
39, 56, 60-64
.  For 
example, urine TDA among a group of workers in direct skin contact with uncured TDI-based foam 
occurred at higher levels compared to non-handlers, even though both groups were exposed to similar 
airborne levels of TDI
64
.  The author suggested that dermal absorption accounted for this large 
difference in TDA levels between the two groups.  However, one limitation in this study was not 
demonstrating whether urinary levels were attributed to skin exposure to the hydrolyzed diisocyanate 
(i.e., diamine) from contaminated surfaces or to the diisocyanate itself.  Because quantitative 
information relating dermal exposure to diisocyanates (e.g., HDI monomer) and biomarker levels is 
lacking, one of our goals was to investigate the relationship between dermal exposure to HDI 
monomer on the skin and plasma HDA levels. 
   Quantification of amines in biological samples requires highly sensitive and selective methods.  
Such methods have been described previously for HDA
46, 48, 63
, TDA
58
, and MDA
65
, and typically 
involve acid hydrolysis of samples and derivatization of the liberated amines with subsequent GC-MS 
analysis.  Therefore, the total HDA concentration measured in hydrolyzed plasma represents the sum 
of covalently bound HDI monomer and HDA/monoacetyl-HDA oxidation products, as well as non-
covalently bound HDA and its metabolites (e.g., monoacetyl-HDA, diacetyl-HDA), and these levels 
may be directly correlated with levels of HDI monomer in the air and/or on the skin.  Detection limits 
of HDA in hydrolyzed urine reported in previous occupational exposure studies ranged from <0.1 
µg/l
46
 to 3 µg/l
39
.  Two test chamber human exposure studies were unable to detect HDA in 
hydrolyzed plasma of HDI-exposed subjects
43, 46
. 
   The objectives of this study were to (i) quantify HDA in hydrolyzed plasma of 46 auto-body shop 
workers applying HDI-containing clearcoat through GC-MS analysis, (ii) investigate the relationship 
between plasma HDA levels and external exposure to HDI monomer (dermal and inhalation), and (iii) 
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investigate personal protective equipment (PPE) use (i.e., coverall and glove use, respirator type) and 
work environment (i.e., paint booth type, location) as modifiers of internal dose. 
 
2.3 Methods 
2.3.1 Chemicals 
HPLC grade toluene (≥ 99.9%), HPLC grade ethyl acetate, certified American Chemical Society 
(ACS) grade sulfuric acid (H2SO4), sodium sulfate anhydrous, laboratory grade potassium phosphate 
monobasic (KH2PO4), ACS grade sodium chloride (NaCl), and certified ACS grade sodium 
hydroxide (NaOH) were obtained from Fisher Scientific (Hampton, NH).  HDA (98%), 1,7-
heptanediamine (HpDA) and derivatization grade heptafluorobutyric anhydride (HFBA) were 
obtained from Sigma-Aldrich (St. Louis, MO).  Human plasma from whole blood (EDTA, potassium) 
was obtained from Biological Specialty Corporation (Colmar, PA) and stored at –40ºC in 5 ml 
aliquots. 
 
2.3.2 Preparation of standard solutions 
   Stock solutions of HDA and HpDA (1 mg/ml) were prepared by dissolving 25 mg of the amine in 
25 ml 1M H2SO4 and diluted 1:1000 to a final concentration of 1 μg/ml.  The solutions were stored at 
–40ºC for up to one month.  An internal standard solution (IS) was prepared by further dilution 
(1:100) of the HpDA solution in 1M H2SO4 to 10 ng/ml.  An HDA standard solution was prepared by 
further dilution (1:2) of the HDA solution in 1M H2SO4 to 0.33 μg/ml.  Just prior to the sample work-
up procedures HDA calibration standards (n = 8), in the range of 0 – 2 μg/l plasma, were prepared in 
duplicate by making 1:1 serial dilutions from the HDA standard solution in 1M H2SO4 and spiking 12 
μl of each diluted standard to 1 ml control plasma.  To each HDA calibration standard, 12 μl of IS 
was added for a final concentration of 0.12 μg/l plasma. 
 
25 
 
2.3.3 Instrumental analysis 
   Samples were analyzed by gas chromatography-mass spectrometry (GC-MS; Thermo Trace GC 
Ultra interfaced with a PolarisQ ion trap mass spectrometer and AI/AS 3000 injector, and Xcalibur 
1.4 SR1 software, Thermo Electron Corporation, Austin, TX).  Injections (1 µl) were made under 
splitless mode of 30 s with injector temperature of 220ºC.  Separation of the samples was carried out 
with a GC capillary column (DB5-MS, 30 m  0.25 mm ID, 0.1 µm film thickness; Agilent 
Technologies, Palo Alto, CA).  The ion source and GC transfer line temperatures were maintained at 
150ºC and 260ºC, respectively.  Helium was used as the carrier gas with a constant flow of 1 ml/min. 
The GC oven temperature program was 50ºC (1.0 min) to 155ºC at 10ºC/min, 155ºC to 185ºC at 
2ºC/min, and 185ºC to 300ºC at 25ºC/min (final temperature held for 10 min).  Ions were monitored 
in negative ion chemical ionization mode using methane as the reagent gas (1.8 ml/min).  Mass 
spectra were acquired in the mass-to-charge ratio (m/z) range 400 – 500.  Quantification of HDA 
derivatives in plasma samples was performed using a linear calibration graph of peak-area response 
of HDA to peak-area response of IS ratio versus concentration of HDA in calibration standards (r
2
 = 
0.998).  The retention times of derivatized HDA and HpDA were 15.1 and 16.6 min, respectively.  
The most abundant fragment ions were produced from losses of 3 fluorine and 3 hydrogen groups 
([M – H] -  [M – H – 60] -), yielding m/z 448 (HDA) and 462 (HpDA) (Figure 2.1). 
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Figure 2.1  Gas chromatogram and mass spectra of heptafluorobutyryl derivatives of 0.50 µg/l 
HDA (A1) and 0.12 µg/l HpDA (B1) in a plasma sample. A1 and B1 were recorded at 
m/z 448 and 462, corresponding to the heptafluorobutyryl derivative of HDA (A2) and 
the heptafluorobutyryl derivative of HpDA (B2). 
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2.3.4 Work-up procedures 
2.3.4.1 General procedure for plasma samples.  The sample work-up procedure was adapted from a 
previously published method describing the analysis of HDA in urine 
48
.  Duplicate glass vials 
containing 1 ml plasma (± HDA) and 12 µl of IS (0.12 µg/l plasma) were hydrolyzed with 100 µl of 
concentrated H2SO4 at 100ºC for 16 h.  The sample vials were cooled to room temperature and 0.5 g 
NaCl was weighed and added to the vials.  A solution of saturated NaOH (4 ml) was added and the 
liberated amines extracted, with vortexing between extractions, into toluene (3  2 ml).  The toluene 
layers were transferred to new tubes and 20 µl of HFBA added to derivatize the amines.  The vials 
were vortexed for several seconds and heated at 55ºC for 1 h.  The excess reagent was removed by 
extraction with phosphate buffer solution (4 ml of 1M KH2PO4, pH 7).  The toluene layers were 
transferred to new vials and dried over sodium sulfate.  The samples were dried under nitrogen using 
a TurboVap
®
 LV Evaporator (Zymark Center; Hopkinton, MA).  The dried residues were dissolved in 
200 µl ethyl acetate and placed in an ultrasonic bath for several minutes.  The sample solutions were 
transferred to GC vial inserts and evaporated to dryness using a SpeedVac
®
 (Savant Instruments Inc., 
Holbrook, New York).  The dried residues were dissolved in 60 µl ethyl acetate.  One reagent blank 
and two calibration standards were prepared with every set of plasma samples collected from the 
workers.  The samples were analyzed by GC-MS as described above. 
 
2.3.4.2 Stability of HDA in plasma during hydrolysis.  Because the stability of amine metabolites in 
biological samples may be related to the hydrolysis conditions, we compared changes of hydrolysis 
time on the concentration of HDA in plasma.  The concentration of HDA in plasma after 0, 4, and 16 
h hydrolysis times at 100ºC with 100 µl concentrated H2SO4 was measured.  Stock solutions of HDA 
and HpDA were prepared in 1M H2SO4, as described above, and spiked into 1 ml blank plasma for a 
final HDA concentration of 2 µg/l and IS concentration of 0.12 µg/l.  To one set of HDA spiked 
plasma (N = 5), the work-up procedure was performed without hydrolysis (i.e., no addition of 
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concentrated H2SO4 and heating at 100ºC).  A second set of HDA spiked plasma solutions (N = 5) 
was prepared and the work-up procedure was performed involving hydrolysis for 4 h in concentrated 
H2SO4 and IS added after hydrolysis.  A third set of HDA spiked plasma solutions (N = 5) was 
prepared and the work-up procedure was performed involving hydrolysis for 16 h in concentrated 
H2SO4 and IS added after hydrolysis.  The amine residues for all sample sets were dissolved in 60 µl 
ethyl acetate and analyzed by GC-MS. 
 
2.3.4.3 Method detection limit (MDL) determination.  The USEPA
66
 describes the MDL as the 
minimum concentration of a substance that can be measured and reported with 99% confidence that 
the analyte concentration is greater than zero, and is based on the approach of Glaser and 
colleagues
67
.  To calculate the MDL, a minimum of seven replicate (n) spikes are prepared at an 
appropriately low concentration (generally 1 to 5 times the expected MDL) and processed through the 
entire analytical method.  Therefore, we spiked 9 plasma samples with 0.12 µg/l HDA and 0.12 µg/l 
IS, and the work-up procedure performed as previously described for HDA analysis.  The MDL was 
calculated using the following general formula: 
MDL = s × t(n-1, 1-α = 0.99) 
where 
n = number of replicate spike determinations at 1 to 5 times the estimated MDL. 
s = standard deviation of measured concentration of n spike determinations. 
t = Student’s t value at n-1 degrees of freedom and 1-α (99%) confidence level.  At n = 9 and   α = 
0.1, then t = 2.896, and 
α = level of significance 
Thus, based on values in our study: s = 7 ng/l, n = 9, and t = 2.896 at α = 0.1, the MDL was calculated 
at 0.02 µg/l. 
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2.3.5 Biomarker and exposure measurements  
   One blood sample (10 ml) was obtained at the end of the work-shift from each of the 46 spray 
painters applying HDI-containing paint in auto-repair shops in North Carolina (n = 14) and in 
Washington (n = 32).  Blood samples were collected during each sampling visit when workers 
consented (112 total blood samples).  No more than 3 sampling visits (at least 3 weeks apart) were 
made for each worker.  Blood was collected in heparin and EDTA tubes, and the plasma separated 
within 24 h of collection.  After the plasma was isolated, samples were stored at –40ºC until analyzed.  
Samples (1 ml) were prepared in duplicate and the work-up procedure performed as outlined above.  
Urine was also collected from the workers throughout the workday, and stored at –40ºC until 
analyzed.  Results for HDA in hydrolyzed urine are published elsewhere
50
. 
Breathing-zone and dermal exposure measurements among these occupationally exposed spray 
painters have been published elsewhere
41, 53
.  Briefly, a personal air sample in the worker’s breathing-
zone was collected during each spray-painting operation of clear-coat using a 1-stage or 2-stage filter 
sampling system housed in a 37-mm polystyrene cassette (SKC Inc., Eighty Four, PA, USA) attached 
to a high-flow air pump operating at 1.0 l/min (SKC).  The 2-stage sampler used in this study 
contained an untreated polytetrafluoroethylene pre-filter (designed to collect diisocyanate aerosols) 
and a glass-fiber filter impregnated with derivatizing agent (designed to collect and derivatize 
diisocyanate vapors).  The one-stage sampler was identical to the two-stage samplers except that the 
pre-filter was not included in the cassette.  For 8 sampling visits (3 workers), air sampling using 1- 
and 2-stage samplers was performed side-by-side.  HDI on the skin was collected using 3 consecutive 
tape-strips (10 cm
2
) applied to 6 different sites on the worker’s body (e.g., right and left forearms, 
hands, and neck) after each paint task.  Skin and air samples were analyzed by LC-MS as previously 
described by Fent and colleagues
41, 53
.  An algorithm described by Fent and colleagues was used to 
calculate the whole-body concentration of HDI in the skin (ng/mm
3
) for each worker and paint task
41
. 
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   Work diaries and questionnaires about workers’ physical characteristics (e.g., age, height, weight), 
type and frequency of PPE use (e.g., coveralls, respirator, gloves), work environment (e.g., paint 
booth, number of paint tasks per week), and duration of paint tasks were completed during each visit. 
 
2.3.6 Variable construction 
   The breathing-zone concentration (BZC) of HDI monomer for each paint task (µg/m
3
) was 
multiplied by the total paint time (min) for each task and summed together to obtain a daily 
cumulative air exposure (DCAE).  Each DCAE value was multiplied by the average male breathing 
rate (0.023 m
3
/min) to estimate the HDI inhalation exposure (µg)
68
.  We also estimated the respirator-
adjusted HDI inhalation exposure after dividing each DCAE value by the OSHA Assigned Protection 
Factor (APF) based on respirator type
69
: none, APF = 1; air purifying (half face), APF = 10; air 
purifying (full facepiece), APF = 50; supplied air (full facepiece or hood), APF = 1000; PAPR (full 
facepiece or hood), APF = 1000.  Among visits where 1- and 2-stage air samplers were used side-by-
side, we selected 1-stage air data for regression and statistical analyses based on findings by Fent and 
colleagues
53
.  The HDI monomer dermal exposure concentrations (µg/m
2
) for each paint task were 
multiplied by body surface area of the worker (m
2
) and summed together to estimate the cumulative 
daily dermal exposure (µg).  The internal HDA dose (µg) was calculated by multiplying the HDA 
concentration (µg/l) in plasma with the individual plasma volume (l), which was determined using 
individual’s body weight70. 
 
2.3.7 Statistical analysis 
   Differences in HDA concentration in spiked plasma at hydrolysis times of 0, 4, and 16 h was 
analyzed using single factor analysis of variance in Excel (Microsoft Office, 2004) at α-level of 0.05.  
The effect of sample treatment on repeatability (intra-group variability) was investigated by 
calculating the percent coefficient of variation (%CV), which was derived as the ratio of the standard 
deviation of replicate samples to the mean and multiplied by 100, among calibration standards and 
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field samples.  The effect of sample treatment on reproducibility (inter-group variability) was 
investigated by comparing the %CV among calibration standards and field samples. 
   Due to the relatively high percentage of non-detectable levels of HDA in hydrolyzed plasma 
samples (24%), multiple imputation (n = 10 imputed datasets) was used to impute plasma HDA data 
below detection limits (i.e., <0.02 µg/l).  Methods for performing multiple imputation of exposure 
data are previously described by Fent and colleagues
41, 53
, and were also applied to plasma HDA.  
Briefly, a lower bound of zero was set for the imputations, and we imputed from truncated 
multivariate normal distributions, with truncation at the MDL.  The geometric mean and geometric 
standard deviation of dose and exposure data were calculated from the log-transformed data (PROC 
MEANS procedure in SAS, version 9.1; SAS Institute, Cary, NC). Statistical analysis of the stratified 
data, according to different workplace covariates, was performed using analysis of variance and 
Tukey-Kramer multiple comparison test (Tukey’s test, PROC GLM procedure) at α-level 0.05 across 
each imputed data set and p-values averaged. 
   SAS PROC MIANALYZE was used to combine the results of the analyses on 10 imputed datasets 
in order to obtain valid estimates and statistical inferences across repeated visits.  Linear mixed 
models for predicting plasma HDA levels were constructed and parameter estimates, as well as the 
restricted maximum likelihood (REML) estimates for the within- and between-worker variance of the 
logged values were obtained using SAS PROC MIXED of the fixed effects, which included location, 
coverall use, glove use, respirator type, and booth type.  Each fixed effect was evaluated one at a time 
with the log-transformed plasma HDA level as the dependent variable, and the p-value of the 
prediction determined.  A significance level of 0.05 was used to investigate these relationships.  The 
variance components covariance structure type was selected based on comparisons of the Akaike’s 
Information Criteria (AIC) across models with competing covariance structures
71
.  The intraclass 
correlation coefficient (ICC), defined as the proportion of total variance explained by the between-
worker variability, and calculated by dividing the between-worker variance by the sum of the 
between- and within-worker variance, was calculated for plasma HDA. 
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   The correlation between biomarker and exposure data was investigated using linear regression 
analysis (PROC CORR procedure in SAS).  PROC MIANALYZE was used to obtain a Pearson’s 
correlation coefficient (r) and p-value from the set of 10 imputed datasets.  We computed Fisher’s z 
transformation of r to determine the 95% confidence intervals on Pearson’s r.  For regression and 
statistical analyses, all continuous values were log-transformed to meet the assumption of normality 
(Shapiro-Wilk W > 0.80). 
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2.4 Results  
2.4.1 Stability of HDA with sample treatment 
   Hydrolysis of HDA spiked plasma samples for up to 16 h did not significantly affect the 
concentration of HDA (p = 0.31).  This result is similar to HDA stability in water and urine under 
similar hydrolysis conditions described by Marand and colleagues
72
.  The detection limit (MDL) of 
the analysis, from spiked plasma samples, was 0.02 µg/l.  The repeatability among standards and field 
samples was assessed using the %CV.  The %CV among replicate calibration standards (range of 0 – 
2 µg/l) was in the range of 0.3 – 5%, demonstrating good repeatability.  The %CV among replicate 
field samples (range of <0.02 – 0.92 µg/l) was in the range of 0.5 – 20%, demonstrating lower 
repeatability compared to calibration standards with spiked HDA.  Thus, sample treatment affected 
the reproducibility of the method between calibration standards (spiked standards) compared with 
field samples.  The higher variability of amines in samples compared to spiked standards has been 
observed previously using different biological matrices
72
.  This may be a due to the efficiency of the 
hydrolysis step in cleavage of HDA – protein covalent bonds among field samples yielding greater 
variability in recovered HDA, whereas spiked plasma does not require bond cleavage to extract HDA. 
 
2.4.2 HDA plasma levels in occupationally exposed workers 
   The range of HDA concentrations in hydrolyzed plasma samples was ≤0.02 – 0.92 µg/l.  After 
imputing values for samples <MDL (24%) and adjusting for individual plasma volume, the geometric 
mean (GM) and geometric standard deviation (GSD) for the plasma HDA dose was 0.29 µg and 3.53, 
respectively.  Of the 46 workers participating in the study, we collected blood on exactly 2 repeated 
visits for 10 workers, and 3 repeated visits for 28 workers.  Dermal and breathing-zone samples were 
not collected from 4 workers during 4 of the 112 sampling visits because no paint tasks were 
performed on those days.  Therefore, we analyzed 108 plasma samples from 46 workers with 
corresponding dermal and breathing-zone measurements that were used in regression and statistical 
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analyses.  The GM and GSD for dermal HDI monomer exposure was 4.9 µg and 11.2, respectively, 
and approximately 35% of paint tasks had detectable levels of HDI on the skin.  The GM and GSD 
for unadjusted inhalation exposure was 1.9 µg and 4.8, respectively, and approximately 90% of paint 
tasks had detectable levels of HDI in the breathing-zone of workers. 
 
2.4.3 Linear regression 
   The correlation coefficients and significance of the associations between plasma HDA levels and 
HDI exposure (dermal and inhalation) measured on the same workday are summarized in Table 2.1.  
The correlation between plasma HDA levels and HDI inhalation exposure, adjusted by APF, was 
weak (N = 108, r = 0.10, p = 0.336) compared with that unadjusted by APF (N = 108, r = 0.22, p = 
0.026) (Figure 2.2).  Individual differences in respirator fit and maintenance (e.g., change-out of 
respirator filters), the uptake and elimination kinetics of HDI via the inhalation route, and/or the 
contribution of HDI dermal exposure on plasma HDA level may have obscured the association 
between HDI inhalation exposure and dose. 
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Table 2.1 Correlation between log-transformed plasma HDA levels (µg) and inhalation or 
dermal HDI exposure (µg) measured during the same workday. 
Predictor Variables n
a
 N
b
 
Pearson’s 
r 95% CI
c
 p-value 
HDI Unadjusted Inhalation (µg) 46 108 0.22 0.03 – 0.40 0.026 
HDI Adjusted Inhalation (µg) 46 108 0.10 -0.10 – 0.29 0.336 
HDI Dermal (µg) 46 108 0.22 0.01 – 0.41 0.040 
HDI Dermal (µg)
d
 10 17 0.58 0.06 – 0.85 0.031 
a. Number of workers. 
b. Number of samples. 
c. 95% confidence interval for Pearson’s r. 
d. Inhalation exposure to HDI <0.005 µg. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Linear regression of the log-transformed plasma HDA levels (µg) versus the log-
transformed unadjusted HDI inhalation exposure (µg) measured on the same 
workday (N = 108; r = 0.22; p = 0.026) for visits 1-3. 
 
   HDA concentration in hydrolyzed plasma may be partially derived from the cleavage of long-lived 
albumin conjugates during hydrolysis, as was demonstrated for MDI exposures 
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, and may, thus, be 
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collection, the association improved (N = 29, r = 0.57, p = 0.0014) (Table 2.2 and Figure 2.3).  In 
addition, the correlation improved between plasma HDA levels and adjusted inhalation exposure to 
HDI occurring ~20 – 60 days before blood collection (N = 29, r = 0.44, p = 0.018). 
 
Table 2.2 Correlation between log-transformed plasma HDA levels (µg) and inhalation            or 
dermal HDI exposure (µg) ~20 – 60 days prior to blood collection.  
Predictor Variables n
a
 N
b
 
Pearson’s 
r 95% CI
c
 p-value 
HDI Unadjusted Inhalation (µg) 26 29 0.57 0.14 – 0.78 0.0014 
HDI Adjusted Inhalation (µg) 26 29 0.44 0.06 – 0.69 0.018 
HDI Dermal (µg) 26 29 0.36  -0.08 – 0.65 0.053 
a. Number of workers. 
b. Number of plasma samples. 
c. 95% confidence interval for Pearson’s r. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3  Linear regression of the log-transformed plasma HDA levels (µg) versus the log-
transformed unadjusted HDI inhalation exposure (µg) occurring ~20 – 60 days prior 
to blood collection (N = 29; r = 0.57; p = 0.014). 
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dermal exposure levels measured on the same workday when workers’ exposure through the 
inhalation route was minimized (i.e., measured air levels <MDL).  The correlation between plasma 
HDA levels and HDI dermal exposure was low (N = 108, r = 0.22, p = 0.040) compared with that 
among workers where adjusted inhalation exposure was very low (<MDL/5 ≈ 0.005 µg) (N = 17, r = 
0.58, p = 0.031) (Table 2.1).  In addition, the correlation between plasma HDA levels and HDI 
dermal exposure occurring ~20 – 60 days before blood collection, did not improve the association (N 
= 29, r = 0.36, p = 0.053) (Table 2.2).  The large percentage of paint tasks with non-detectable HDI 
measures on the skin (65%), exposure through the inhalation route, as well as other workplace and 
individual factors (e.g., PPE use, uptake and elimination kinetics of HDI through the skin) may be 
obscuring the association between internal dose and dermal exposure. 
 
2.4.4   Statistical models 
   We also investigated whether differences in PPE use (coveralls, gloves, respirator type) and 
sampling location (NC versus WA) would significantly modify plasma HDA levels.  The GM and 
GSD values, as well as ranges for plasma HDA levels stratified by these various workplace covariates 
are summarized in Table 2.3.  After implementing analysis of variance in SAS, insignificant 
differences in the GM of plasma HDA levels were observed between location NC and WA (mean 
difference = 0.02 µg, p = 0.778), coverall non-users and users (mean difference = 0.09 µg, p = 0.097), 
and glove non-users and users (mean difference = 0.03 µg, p = 0.629). 
   Insignificant differences among the different respirator types were also observed for plasma HDA 
levels (p = 0.305), unadjusted HDI inhalation exposure (p = 0.460), and HDI dermal exposure (p = 
0.250), using analysis of variance and Tukey’s test in SAS.  However, we noted that PAPR users had 
a slightly higher GM for plasma HDA level (0.44 µg) compared to the other booth types (Table 2.3), 
which may be related to maintenance and/or proper fit of respirator.  Even though most workers 
(98%) wore a respirator during spraying, there is the potential for inhalation exposure through 
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respirator filters and mask resulting from inadequate change-out of filters and/or loose-fitting mask 
due to improper fit, which was not factored into the adjusted inhalation exposure calculations. 
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Table 2.3 Summary of plasma HDA levels (µg) in 46 spray painters stratified by workplace 
covariates. 
Covariate n
b
 N
c
 
Summary Statistics  
GM GSD Range p-value
d
 
Location       
North Carolina 13 30 0.20 3.83 <0.02-1.58 0.778 
Washington 33 78 0.18 3.46 <0.02-3.61   
Coveralls       
no 18 35 0.25 3.57 <0.02-1.58 0.097 
yes 32 73 0.16 3.48 <0.02-3.61   
Gloves       
no 13 22 0.21 3.51 <0.02-1.54 0.629 
yes 39 86 0.18 3.57 <0.02-3.61   
Respirator       
Air purifying (half)  35 80 0.17 3.24 <0.02-2.85 0.305 
Air purifying (full) 1 3 0.20 4.5 0.03-0.64  
Supplied air (full or hood) 8 17 0.18 5.31 <0.02-3.61  
PAPR (full or hood)  4 7 0.44 2.48 0.16-2.47  
none 1 1 0.79       
Overall 46 108 0.29 3.53 0.02-3.61   
GM, geometric mean; GSD, geometric standard deviation; PAPR, powered-air purifying respirator 
a. Among workers performing paint tasks on day of sample collection (N = 108).  Multiple imputation (n 
= 10 imputed datasets) was used to impute plasma data below MDL. 
b. Number of workers. 
c. Number of samples 
d. p-value determined using analysis of variance. 
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   Table 2.4 summarizes plasma HDA levels as well as HDI inhalation (adjusted and unadjusted) and 
dermal exposures stratified by paint booth type with p-values determined using analysis of variance 
testing in SAS.  The plasma HDA levels was significantly lower among workers painting in a 
downdraft ventilated booth compared to a semi-downdraft booth (p = 0.0108) using Tukey’s test.  
HDI dermal and inhalation (unadjusted for APF) exposures were also significantly lower among 
downdraft booth users compared to the other booth types (p < 0.0001).  The similar trend for HDI 
exposure levels (dermal and inhalation) and plasma HDA levels demonstrate that paint booth type 
may be an important modifier of the relationship between exposure and internal dose.  These findings 
also reaffirm previous evidence of differential HDI exposure levels by booth type indicating that the 
downdraft booth may produce lower particulate exposures relative to other booth types
31
.  
Additionally, among workers painting in a downdraft booth (n = 31), HDA plasma levels were 
significantly lower among workers wearing coveralls compared to those not wearing coveralls (p = 
0.010), indicating a protective effect from coverall use and that dermal exposure is contributing to 
internal dose. 
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Table 2.4 Summary of measurements in 46 spray painters
a
 stratified by paint booth type. 
Variable Booth Type n
b
 N
c
 
Summary Statistics  
GM GSD Range p-value
d
 
Plasma HDA (µg) Downdraft 31 72 0.15 3.48 <0.02-2.85 0.0108 
 Semi-downdraft 10 21 0.35 3.53 <0.02-3.61  
 Crossdraft 6 15 0.26 2.79 0.03-0.83  
 Overall 46 108 0.29 3.53 <0.02-3.61  
HDI Adjusted 
Inhalation (µg) 
Downdraft 31 72 0.05 9.35 <0.0002-5.91 0.0051 
 Semi-downdraft 10 21 0.05 10.5 0.001-1.70  
 Crossdraft 6 15 0.39 5.04 0.013-4.94  
 Overall 46 108 0.07 9.76 <0.0002-5.91  
HDI Unadjusted 
Inhalation (µg) 
Downdraft 31 72 1.18 4.46 <0.02-59.1 <0.0001 
 Semi-downdraft 10 21 6.88 2.49 0.84-21.4  
 Crossdraft 6 15 3.33 4.8 0.13-49.4  
 Overall 46 108 1.92 4.84 <0.02-59.1  
HDI Dermal (µg) Downdraft 31 72 1.94 7.31 <0.10-1,023 <0.0001 
 Semi-downdraft 10 21 28.8 8.82 0.24-440  
 Crossdraft 6 15 33.3 8.91 1.14-538  
 Overall 46 108 4.86 11.2 <0.10-1,023  
GM, geometric mean; GSD, geometric standard deviation 
a. Among workers performing paint tasks on day of sample collection (N = 108).  Multiple imputation  
(n = 10 imputed datasets) was used to impute plasma data below MDL. 
b. Number of workers. 
c. Number of samples. 
d. p-value determined using analysis of variance. 
 
   The linear mixed model results for predicting plasma HDA level are summarized in Table 2.5.  A 
large proportion (95%) of the total variance in plasma HDA level is attributed to the within-worker 
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variance (σ2w), whereas ~5% of the total variance is explained by the between-worker variance (σ
2
b) 
(Table 2.5).  The within-worker variance represented a majority of the total variance even when 
stratifying for location (0 = NC, 1 = WA), coverall or glove use (0 = no, 1 = yes), and respirator type 
or booth type (0 = no, 1 = yes for each type) as a fixed-effect covariate in the prediction of plasma 
HDA level in our mixed model.  In addition, location (p = 0.806), coverall use (p = 0.114), glove use 
(p = 0.758), and use of various respirator types (p = 0.068 – 0.942) were not-significant predictors of 
plasma HDA levels.  On the other hand, downdraft (p = 0.004) and semi-downdraft (p = 0.012) booth 
types were significant predictors of plasma HDA levels. 
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Table 2.5 Linear mixed models for predicting log-transformed plasma HDA (µg)
a
 in 46 automotive 
spray painters. 
 Covariates
b
 n
c
 N
d
 
Parameter 
Estimates 
REML
e
 
Estimates 
ICC p-value
f
 σ2w σ
2
b 
Intercept 46 108 -1.676 1.77 0.10 0.05  <0.001 
Location  33 78 -0.071 1.44 0.34 0.19 0.806 
Coveralls  32 73 -0.423 1.55 0.26 0.14 0.114 
Gloves  39 86 -0.096 1.80 0.09 0.05 0.758 
Respirator Type        
Air purifying (half) 35 80 -0.407 1.48 0.12 0.08 0.137 
Air purifying (full) 1 3 0.058 2.40 NA NA 0.942 
Supplied Air (full or hood) 8 17 -0.034 3.25 0.11 0.03 0.934 
PAPR (full or hood) 4 7 0.931 0.66 0.19 0.22 0.068 
none 1 1 1.452 NA NA NA 0.258 
Booth Type        
Downdraft 31 72 -0.745 1.80 0.02 0.01 0.004 
Semi-downdraft 10 21 0.774 1.86 0.03 0.02 0.012 
Crossdraft 6 15 0.377 1.04 0.18 0.15 0.310 
REML, restricted maximum likelihood; ICC, intraclass correlation coefficient; NA, not applicable 
a.
 Multiple imputation (n=10 imputed datasets) was used to impute air-sampling data below MDL. 
b.
 Each fixed-effect dichotomous covariate tested in the linear mixed model for log-transformed plasma HDA 
level (dependant variable); location (NC=0, WA=1), coveralls (no=0, yes=1), gloves (no=0, yes=1) respirator 
type (no=0, yes=1 for each type), booth type (no=0, yes=1 for each type). 
c.
 Number of workers. 
d.
 Number of samples. 
e.
 Restricted maximum likelihood estimates of the log-transformed data for the within-worker (σ2w) and 
between-worker variance (σ2b). 
f.
 p-value is based on F-tests of fixed effects. 
 
44 
 
2.5 Discussion  
   We collected blood samples from 46 automotive spray painters at the end of the workday, which 
yielded internal dose estimations of HDI exposure.  Using linear regression, as well as multiple 
comparisons testing of workplace covariates and linear mixed models to predict plasma HDA level, 
we investigated relevant exposure pathways and identified significant predictors of internal dose.  
However, there were several limitations that warranted consideration in the interpretation of our 
results. 
   In this study, we investigated HDA concentration in hydrolyzed plasma as a biomarker of exposure 
to HDI monomer.  However, HDI oligomers, isocyanurate, uretidone, and biuret, were also present in 
the workers’ breathing-zone and on the skin, with the highest levels for both air and skin occurring 
for isocyanurate.  Because current knowledge about oligomer absorption, metabolism, and the 
corresponding biomarkers that best reflect exposure to these compounds is lacking, we treated HDA 
as the only validated biomarker of exposure to HDI monomer.  Consequently, the relationship 
between plasma HDA level and exposure to HDI oligomers was not investigated, leaving future 
exposure assessment studies to consider how best to estimate dose of these compounds. 
   Because we investigated HDA concentration in hydrolyzed plasma, we were unable to differentiate 
the proportion of unconjugated to protein-conjugated HDI/HDA or metabolic products, monoacetyl-
HDA or diacetyl-HDA in plasma.  Consequently, individual differences in HDA acetylation (fast 
versus slow), which may affect HDI metabolism rates and extent of protein adduct formation, as was 
demonstrated by Brorson and colleagues for urinary HDA levels
21
, would have been masked by the 
acid treatment.  Individuals who are fast acetylators would favor the metabolic pathway leading to the 
formation of diacetyl-HDA, which is excreted directly into the urine, rather than the formation of 
protein adducts via the oxidation pathway.  Also, Pauluhn and colleagues
56
 observed differences in 
ratio of acetylated MDA/MDA hemoglobin adducts between inhalation and dermal exposure routes in 
exposed rats, and, thus, exposure route may influence metabolic pathways and elimination kinetics of 
these compounds.  Methods for distinguishing between these pathways in monitoring for HDA 
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biomarkers may aid to identify relevant mechanisms contributing to biological effects.  Further 
investigation into the proportion of unconjugated versus conjugated HDA and acetylated HDA 
protein adducts would also provide insights into the half-life of these compounds in the blood and 
their possible use as indicators of cumulative exposure to HDI. 
   Estimating inhalation exposure from breathing-zone concentrations is challenging due to the 
presence of exposure modifiers, such as respirator use.  Adjusting air concentrations by the APF, 
according to respirator type, in order to estimate inhaled concentrations has several limitations 
including the inability to account for improper fit and/or maintenance.  Air-purifying respirators (e.g., 
half-face air purifying), that implement filtration for reducing inhalation exposure, may not 
sufficiently remove diisocyanate aerosols, particularly if workers do not follow routine change-out of 
filters
35
.  Consequently, adjusting breathing-zone concentration by APF may under-estimate workers’ 
true exposure if proper fit-testing and scheduled maintenance are not employed.  Therefore, the 
correlation between plasma HDA level and inhalation exposure to HDI, adjusted by APF, needs to be 
interpreted with caution due to these limitations in estimating inhaled dose. 
   One of the main advantages in measuring blood biomarkers of HDI exposure would be to obtain 
internal dose measures of past or cumulative exposures from the formation of protein adducts.  
Assuming the modified proteins are stable, these markers may be indicative of cumulative 
diisocyanate exposure over the half-life of these proteins, such as albumin (~3 weeks).  The presence 
of protein adducts may explain why the association between plasma HDA level and HDI inhalation 
exposure improved when HDA levels were correlated with exposures measured approximately 20–60 
days prior to blood collection compared to same day exposures.  When we investigated the 
relationship between plasma HDA levels and HDI inhalation exposure measurements from >60–200 
days before blood collection, the association was weaker (N = 37, r = 0.07, p = 0.66).  Assuming that 
the majority of plasma HDA was in the form of albumin adducts, most of these products would have 
been cleared over this time period.   Our relationships with inhalation exposure should be interpreted 
with caution due to the limitations in estimating workers’ inhaled dose through respirators.  Unlike 
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plasma, urine HDA concentration has been demonstrated to be a good indicator of recent (short-term) 
inhalation exposure to HDI, due to the evidence for a fast elimination phase (1.2 – 2.5 hours) 46, 49. 
   The correlation between plasma HDA level and dermal HDI exposure should be interpreted with 
caution due to the large percentage of paints tasks (65%) with non-detectable levels of HDI on the 
skin.  Although tape-strips of the skin were collected after each paint task, the possibility of rapid 
formation of HDI-keratin adducts on the skin and/or rapid absorption through the stratum corneum 
would contribute to the large number of non-detects of HDI monomer on the skin.  An interesting 
observation was the slightly higher plasma HDA levels between non-coverall users compared with 
coverall users (p = 0.097), which may suggest an association between plasma HDA level and dermal 
HDI exposure modified by skin protection.  Further research on the dermal penetration of HDI 
monomer and oligomers may provide information on the uptake and elimination rates from this route 
of exposure and the extent of its impact on internal dose levels. 
   Another important point to consider is the high collinearity between dermal and HDI inhalation 
exposure (r = 0.77, p < 0.0001), and the impact of that association with attempts at interpreting 
causation with respect to plasma HDA concentration.  Therefore, establishing relative significance of 
either route on internal dose levels based on the strength of the correlations between plasma HDA 
levels and exposure measures may be limited in this study.  The influence of multiple exposure routes 
and the possible differences in metabolism, uptake, and elimination rates for each of these exposure 
routes, may contribute to the large unexplained within-worker variability in plasma HDA levels 
among the workers in this study.  Although significant correlation (p < 0.05) between plasma HDA 
level and dermal or inhalation exposure to HDI was observed, the large unexplained variance in 
plasma HDA levels prevents drawing strong conclusions about the dominant exposure pathway. 
   Of the four plasma samples collected from four workers who did not paint on collection day, two 
plasma samples had detectable concentrations of HDA (0.08 and 0.09 µg/l).  These workers did not 
enter the paint booth during spray-painting tasks nor were they involved in mixing of the paint.  
However, the workers reported painting within the past 5 working days.  This implies for the presence 
47 
 
of HDA adducts in plasma that could be related to cumulative HDI exposure.  Another possible 
explanation is a potential for dermal exposure to trace amounts of HDA (resulting from HDI 
hydrolysis) from contaminated surfaces.  This could result in “false-positive” readings of HDI 
exposure and contribute to the large variability in internal dose.  Thus, biomarker measures 
integrating dosimeters of exposure should also be accompanied by adequate air and dermal 
monitoring across repeated visits. 
   The large variability in plasma HDA levels when correlated with dermal or inhalation exposure to 
HDI, as well as the large unexplained within-worker variance, reflect the limitations of using plasma 
HDA measurements as markers of short-term exposure to HDI.  The improvement in the association 
between plasma HDA level and past HDI inhalation exposure, occurring ~20–60 days before blood 
collection, indicates the presence of plasma protein adducts with longer half-lives.  Thus, the 
detection and measurement of HDA in the plasma may provide important clues linking cumulative 
HDI exposure, the evaluation of workplace protection controls, and the relevant metabolic pathways 
leading to sensitization. 
   The presence of HDI oligomers (i.e., isocyanurate, biuret, uretidone) in the breathing-zone and in 
the skin of these workers at higher levels relative to HDI monomer, stresses the importance of 
investigating additional biomarkers related to HDI oligomer exposures.  Future studies investigating 
individual differences in HDI albumin and hemoglobin adduct levels and half-lives in the blood will 
provide further knowledge of how long these biomarkers may remain in systemic circulation and, 
thus, how exposure patterns may contribute to immune response, sensitization, and development of 
diisocyanate-induced asthma. 
 
2.6 Conclusions 
   We have applied a sensitive method for quantifying HDA in hydrolyzed plasma samples collected 
in the occupational exposure setting.  This study reveals the potential use of plasma HDA as a marker 
of cumulative inhalation exposure to HDI, as well as the possible contribution of dermal exposure to 
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internal dose levels.  Users of the downdraft paint booth had significantly lower plasma HDA levels, 
as well as inhalation and dermal HDI exposure levels compared to the other booth types, and booth 
type was a significant predictor of plasma HDA levels in the linear mixed model.  However, the 
investigation of workplace covariates did not adequately explain the within-worker variability in 
plasma HDA levels, and the low correlations between HDI inhalation and dermal exposure reveals 
the limitation of using plasma HDA as a marker of short-term exposure to HDI.  Other environmental 
factors, as well as the uptake and elimination kinetics of HDI via dermal and inhalation exposure 
routes, and the formation of protein adducts need to be further investigated. 
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3.1 Abstract 
   1,6-hexamethylene diisocyanate (HDI) is extensively used in the automotive repair industry and is a 
commonly reported cause of occupational asthma in industrialized populations.  However, the exact 
pathological mechanism remains uncertain.  Characterization and quantification of biomarkers 
resulting from HDI exposure can fill important knowledge gaps between exposure, susceptibility, and 
the rise of immunological reactions and sensitization leading to asthma.  Here, we discuss existing 
challenges in HDI biomarker analysis including the quantification of N-acetyl-1,6-hexamethylene 
diamine (monoacetyl-HDA) and N,N’-diacetyl-1,6-hexamethylene diamine (diacetyl-HDA) in urine 
samples based on previously established methods for HDA analysis.  In addition, we describe the 
optimization of reaction conditions for the synthesis of monoacetyl-HDA and diacetyl-HDA, and 
utilize these standards for the quantification of these metabolites in the urine of three occupationally 
exposed workers.  Diacetyl-HDA was present in untreated urine at 0.015 – 0.060 µg/l.  Using base 
hydrolysis, the concentration range of monoacetyl-HDA in urine was 0.19 – 2.2 µg/l, 60-fold higher 
than in the untreated samples on average.  HDA was detected only in one sample after base 
hydrolysis (0.026 µg/l).  In contrast, acid hydrolysis yielded HDA concentrations ranging from 0.36 
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to 10.1 µg/l in these three samples.  These findings demonstrate HDI metabolism via N-acetylation 
metabolic pathway and protein adduct formation resulting from occupational exposure to HDI. 
 
3.2  Introduction 
   Biological monitoring of diisocyanate exposure through the analysis of diisocyanate-derived 
diamines in the urine of exposed individuals has been performed for a few decades (Rosenberg et al., 
1986).  However, the relationship of these diamines with dermal and inhalation exposure measures 
has been more difficult to discern due to the lack of a standardized method to assess dermal exposure, 
as well as the low sensitivity and poor specificity of analytical methods for biomarker quantification.  
In addition, workers receive dermal and inhalation exposure to different forms of diisocyanates (e.g., 
monomers, oligomers, and polymers) simultaneously, further complicating attempts to investigate the 
relationship between exposure and dose.  Nevertheless, several volunteer and occupational studies 
have demonstrated a good association between 1,6-hexamethylene diamine (HDA), in urine or 
plasma, and inhalation exposure to HDI monomer
39, 43, 46, 47, 49
. 
   HDI dermal exposure assessment is much less developed than that of inhalation exposure
22
, 
although the role of dermal exposure in sensitization and diisocyanate-induced asthma has been 
demonstrated
27, 37
.  Several different techniques have been used to detect and/or quantify these levels 
in the workplace including SWYPE pads
34
, wipes
38
, glove washes
39
, and tape-strips
40
.  The lack of a 
standardized and fully validated method to assess HDI dermal exposure has added to the difficulty in 
investigating associations between dermal exposure and internal dose.  Evidence that dermal exposure 
occurs among automotive spray painters stresses the need to validate methods to measure skin 
exposure
41
.  Post-exposure tape-stripping of the skin has the advantage of quantifying dermal 
penetration of HDI, and has the potential to be adapted to collect and measure HDI-keratin adducts 
that have been identified in vivo
23
. 
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   Automotive repair shop workers are becoming increasingly exposed to HDI oligomers (i.e., 
isocyanurate, biuret, uretidone) relative to HDI monomer during spray-painting operations, and 
analytical methods for quantifying specific HDI monomer and oligomers in the breathing-zone and 
skin of exposed workers are available
40, 41, 53
.  Since these compounds differ in size and volatility, 
absorption and metabolism may differ by type of HDI oligomer and between monomer and 
oligomers.  Because exposure to these compounds can now be quantified by LC-MS analysis
73
, 
analytical methods to identify and validate specific biomarkers stemming from HDI monomer and 
oligomers need to be developed in order to help characterize exposure patterns to these compounds, 
as well as to understand their potential role in sensitization and asthma. 
   Measures of exposure levels alone, through tape-stripping of the skin or air monitoring, are 
insufficient to fully understand mechanisms involved in sensitization.  Information on HDI 
metabolism and protein adduct formation has contributed to our understanding of the possible 
mechanisms involved in sensitization and development of diisocyanate-induced asthma
23, 24, 42
.  As 
only 5-10% of diisocyanate-exposed individuals develop asthma
13
, attention has been focused on the 
role of genetic factors in modifying individual susceptibility to asthma.  Polymorphisms in 
glutathione-S-transferase (GST) or N-acetyltransferase (NAT) genes may result in inter-individual 
variation in GST or NAT enzyme activities that are involved in HDI metabolism, and could lead to 
increased risk of disease development
16
.  Thus, highly sensitive and specific analytical methods for 
the quantification of HDI metabolites would improve our understanding of genetic susceptibility 
factors contributing to exposure-disease relationships. 
   Analytical methods for HDA in biological media are hindered by extensive sample processing 
involving lengthy acid or base hydrolysis (4 – 16 h), multiple extraction steps with toluene, 
derivatization and drying of samples
39, 45, 46, 48
, and relatively large volume of plasma required to 
conduct replicate analyses (2 – 4 ml).  Acid hydrolysis releases HDA-protein conjugates from 
biological matrixes and converts the acetyl functional groups on N-acetyl-1,6-hexamethylene diamine 
(monoacetyl-HDA) and N,N’-diacetyl-1,6-hexamethylene diamine (diacetyl-HDA) back to HDA.  
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Thus, the HDA detected following these treatment conditions may be derived from a number of other 
metabolites and adducts, and any individual variability in specific metabolite formation would be 
masked by acid hydrolysis.  Base hydrolysis of hemoglobin has resulted in identification of 4,4’-
methylenedianiline (MDA) and N’-acetyl-4,4’-methylenedianiline (monoacetyl-MDA) hemoglobin 
adducts
19, 65
.  Whether base hydrolysis could liberate albumin and hemoglobin adducts of HDA and 
monoacetyl-HDA or adducts of HDI oligomers, has yet to be determined.  HDA was non-detectable 
in untreated urine while base hydrolysis produced detectable levels of HDA
45
, indicating that HDA 
may be covalently bound to proteins, and/or metabolized to other products such as diacetyl-HDA.  
Therefore, analytical specificity for HDI exposure biomarkers must be further developed to determine 
individual differences in specific metabolite formation related to HDI monomer and oligomer 
exposure. 
   Because no studies have been conducted to quantify monoacetyl-HDA or diacetyl-HDA in 
biological samples, and analytical standards are not commercially available, optimized conditions for 
their synthesis and detection are not well established, leading to variable analytical conditions being 
reported in a few studies
21, 74, 75
.  Brorson and colleagues (1990) reported conditions for the synthesis 
of monoacetyl-HDA using a 1:1 molar ratio of acetic anhydride to HDA in acetonitrile and reacting 
for 2 h
21
.  However, the final results for monoacetyl-HDA in urine samples were only “semi-
quantitative” because monoacetyl-HDA standards were not purified or fully characterized.  In 
addition, the individuals in their study were orally exposed to HDA, not HDI.  Thus, monoacetyl-
HDA and diacetyl-HDA metabolites among HDI exposed workers, and whose exposure occurs 
primarily via dermal and inhalation routes, need to be further investigated.  Therefore, our intent was 
to (i) modify and improve on existing protocols for monoacetyl-HDA and diacetyl-HDA synthesis 
and quantification, (ii) use these methods to quantify monoacetyl-HDA and diacetyl-HDA in urine 
from three occupationally exposed workers, using GC-MS analysis, and (iii) discuss our current 
understanding of HDI metabolism by integrating these findings with additional reaction pathways. 
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3.3  Materials and Methods 
Solvents and chemicals were purchased from Thermo Fisher (Hampton, NH): HPLC grade (99.9%) 
dichloromethane (#AC61005-0040), ethyl acetate (#AC61006-0040) and acetonitrile (#AC61001-
0040), sodium sulfate anhydrous (certified ACS, #S421-500), acetic anhydride (>99%, #AC14949-
0010), and sodium hydroxide (certified ACS, #S318-500); Sigma Aldrich (St. Louis, MO): 1,6-
hexamethylene diamine (≥99%, #33000), 1,7-diaminoheptane (98%, #D17408), and 
heptafluorobutyric anhydride (HFBA, derivatization grade, #394912). 
 
3.3.1 Reaction with acetic anhydride.  Acetylation of HDA in acetonitrile for synthesis of 
monoacetyl-HDA has been published previously (Brorson et al., 1990a).  Because ethyl acetate has 
been used previously in the GC-MS analysis of HDA in urine and plasma (Rosenberg et al., 2002), 
we were interested in comparing acetylation of HDA carried out in ethyl acetate or acetonitrile.  HDA 
was dissolved in acetonitrile according to Brorson and colleagues (1990)
21
, and in ethyl acetate (2 
mg/ml, 100 ml total volume).  Acetic anhydride was added dropwise with constant stirring at seven 
molar ratios of acetic anhydride to HDA increasing from 0.7:1 to 4:1, (S1A – S7A and S1E – S7E, 
respectively) during which time a precipitate formed.  Solutions were allowed to react at room 
temperature for 2 h with continuous stirring then filtered under vacuum using a 0.22 µm, 25 mm 
nylon filter.  The precipitate collected on filters was dissolved in ethyl acetate (1 mg/ml).  The 
filtrates were dried under N2 and dissolved in ethyl acetate at 1 mg/ml. 
   1,7-Heptanediamine (HpDA), the internal standard (IS) for HDA, was dissolved in ethyl acetate (2 
mg/ml, 100 ml total volume).  Acetic anhydride was added dropwise with constant stirring at 0.9:1 
molar ratio of acetic anhydride to HpDA.  The solution was allowed to react at room temperature for 
2 h with continuous stirring, filtered, and filtrates dried under N2. The dried products were dissolved 
in ethyl acetate to make a 1 mg/ml IS mixture. 
   Each 1 mg/ml sample, synthesized in acetonitrile or ethyl acetate, was diluted 1:1000 in ethyl 
acetate (final concentration = 1 µg/ml).  A solution containing monoacetyl-HDA mixture (S3E) and 
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IS mixture (final concentrations = 1 µg/ml) was also prepared in ethyl acetate.  To 1 ml of these 
diluted samples, 10 µl HFBA was added and reacted for 1 h at 55°C with periodic shaking. 
 
3.3.2 GC-MS analysis.  Samples were immediately analyzed by GC-MS (Thermo Trace GC Ultra 
interfaced with a PolarisQ ion trap mass spectrometer and AI/AS 3000 injector, and Xcalibur 1.4 SR1 
software, Thermo Electron Corporation, Austin, TX) in negative chemical ionization mode, according 
to Flack and colleagues (2009), in scan mode (m/z 200-600) using methane as the reagent gas.  
Injections (1 µl) were made under splitless mode of 30 s with injector temperature of 220ºC.  Samples 
were separated on a GC capillary column (DB5-MS, 30 m  0.25 mm ID, 0.1 µm film thickness; 
Agilent Technologies, Palo Alto, CA).  The ion source and GC transfer line temperatures were 
maintained at 150ºC and 260ºC, respectively.  Helium was used as the carrier gas with a constant 
flow of 1 ml/min.  The GC oven temperature program was 50ºC (1.0 min) to 155ºC at 10ºC/min, 
155ºC to 185ºC at 2ºC/min, and 185ºC to 300ºC at 25ºC/min (final temperature held for 10 min).  
Ions were monitored in negative ion chemical ionization mode using methane as the reagent gas (1.8 
ml/min).  Major ions corresponding to HDA, monoacetyl-HDA, and diacetyl-HDA, as well as 
internal standards, HpDA, N-acetyl-1,7-heptanediamine (monoacetyl-HpDA), and N,N’-diacetyl-1,7-
heptanediamine (diacetyl-HpDA), were identified.  The relative percent abundance of each compound 
(i.e., peak intensity of diamine/sum of peak intensities × 100) was calculated for each molar ratio by 
solvent type (acetonitrile or ethyl acetate). 
 
3.3.3 Reaction time.  HDA was dissolved in ethyl acetate (2 mg/ml, 100 ml total volume) to which 
acetic anhydride (0.9:1 molar ratio acetic anhydride to HDA) was dropwise added with constant 
stirring at room temperature.  At each respective time point (1, 2, 3, 4, and 21 h) 10 ml aliquot of the 
mixture was filtered and the filtrate diluted 1:1000 in ethyl acetate (5 ml final volume).  Solutions 
were reacted with 10 µl HFBA for 1 h at 55ºC and immediately analyzed by GC-MS.  The percent 
abundance of each compound was calculated for each reaction time point. 
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3.3.4 Standard curves (diacetyl-HDA and HDA).  A portion of the synthesized diacetyl-HDA 
solution (S7E) was dried under N2, dissolved in ethyl acetate (1 mg/ml), and diluted to a 
concentration range (0 – 4 µg/ml) in ethyl acetate.  A concentration range of HDA was also prepared 
in ethyl acetate (0 – 1 µg/ml).  To 1 ml diluted samples, 5 µl of 1 mg/ml IS mixture was added.  Each 
solution was derivatized with 10 µl HFBA and allowed to react for 1 h at 55ºC.  Samples were 
immediately analyzed by GC-MS. 
 
3.3.5 Treatment of spiked urine (base hydrolysis vs. no treatment).  To two control (unexposed) 
urine samples (1 ml aliquots), 10 µl of the 1 µg/ml optimized monoacetyl-HDA mixture synthesized 
in ethyl acetate (S3E) was added and shaken (set A).  To two control urine samples (1 ml aliquots), 10 
µl of the 1 µg/ml optimized diacetyl-HDA mixture synthesized in ethyl acetate (S7E) was added and 
shaken (set B).  A reagent blank (1 ml urine) was also prepared, which was not spiked with 
monoacetyl-HDA or diacetyl-HDA mixture.  Aqueous NaOH (32%, 50 µl) was added to one sample 
in set A and B, as well as the reagent blank, shaken for several seconds, and allowed to react at room 
temperature for 20 min, according to Sepai and colleagues (1995)
19
, while the other samples were left 
untreated.  Samples were extracted into 6 ml dichloromethane and dried over sodium sulfate.  Dried 
extracts were transferred to fresh vials and reacted with 10 µl HFBA for 30 min at room temperature.  
The derivatized extracts were dried under nitrogen, reconstituted in 200 µl ethyl acetate, sonicated for 
several minutes, and analyzed by GC-MS. 
 
3.3.6 Analysis of urine samples.  Urine samples were collected from three automotive spray 
painters at the end of the workday who applied HDI-containing paint.  These samples were previously 
analyzed for total HDA using acid hydrolysis (0.36 – 10.1 µg/l) 50, and were analyzed for acetylated 
HDA using base hydrolysis or no treatment (section 3.3.5) and GC-MS (section 3.3.2).  The 
acetylated HDA levels were quantified in duplicate samples against a standard curve of urine spiked 
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with synthesized 1 mg/ml (S3E) amine mixture (final urine concentrations: 0 – 0.09 µg HDA/l, 0 – 
2.1 µg monoacetyl-HDA/l, 0 – 2.8 µg diacetyl-HDA/l).  These standards were subjected to both base 
hydrolysis or no treatment and analyzed by GC-MS.  In addition, breathing-zone and dermal tape-
strip samples were collected during and after each paint task, respectively, and previously analyzed 
by LC-MS
41, 53
.  These data for total urinary HDA in acid-hydrolyzed samples and HDI in breathing-
zone and dermal tape-strip samples have been published
41, 50, 53
. 
 
3.4 Results 
3.4.1 Acetylation of HDA.  GC-MS analysis of the synthesized mixtures in ethyl acetate or 
acetonitrile, as well as untreated urine spiked with the mixtures, revealed that the major ions 
corresponding to derivatized HDA, monoacetyl-HDA, and diacetyl-HDA was m/z 448 [M
-
-H3F3] 
eluting at 13.9 min, 510 [M
-
-H2F2] eluting at 14.9 min, and 552 [M
-
-H2F2] eluting at 16.0 min, 
respectively (Figure 3.1A).  The major ion for HpDA, monoacetyl-HpDA, and diacetyl-HpDA in the 
IS mixture was m/z 462 [M
-
-H3F3] eluting at 15.6 min, 524 [M
-
-H2F2] eluting at 16.6 min, and 566 
[M
-
-H2F2] eluting at 17.8 min, respectively (Figure 3.2).  The mass spectra for each corresponding 
standard peak reflected successive losses of hydrogen (H) and fluorine (F) atoms from derivatized 
parent amines (HDA=508, monoacetyl-HDA=550, diacetyl-HDA=592 g/mol) and IS amines 
(HpDA=522, monoacetyl-HpDA=564, diacetyl-HpDA=606 g/mol).  Ion selection used in 
quantification of each amine was based on the most abundant ion fragment in the mass spectra 
(Figure 3.3).   
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A. Standard mixture synthesized in ethyl acetate. 
 
 
B. Urine spiked with mixture and base-hydrolyzed. 
 
 
Figure 3.1  GC-MS chromatograms (m/z 200-600) of (A) a filtered solution containing HDA, 
monoacetyl-HDA, and diacetyl-HDA synthesized with 0.9:1 molar ratio (acetic 
anhydride to HDA) in ethyl acetate using 2 h reaction time and derivatization with 
HFBA and (B) derivatized extract from control urine spiked with the 0.9:1 molar 
ratio mixture and subjected to base hydrolysis. 
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Figure 3.2  GC-MS chromatogram and most abundant mass fragment ion (m/z) for each amine 
(HDA, monoacetyl-HDA, diacetyl-HDA) and the internal standards (HpDA, 
monoacetyl-HpDA, diacetyl-HpDA) in derivatized extract from base-hydrolyzed 
control urine sample spiked with 0.9:1 molar ratio (acetic anhydride to HDA or 
HpDA) mixtures. 
HDA 
monoacetyl-HDA 
diacetyl-HDA 
HpDA 
monoacetyl-HpDA 
diacetyl-HpDA 
monoacetyl-HDA 
monoacetyl-HpDA 
m/z 448 
m/z 510 
m/z 552 
m/z 462 
m/z 524 
m/z 566 
m/z 294 
m/z 308 
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A. Monoacetyl-HDA in spiked urine. 
 
 
B. Diacetyl-HDA in spiked urine. 
 
Figure 3.3 GC mass spectra (m/z 200 – 600) of monoacetyl-HDA (A) and diacetyl-HDA (B) in 
derivatized extract from untreated control urine sample spiked with 0.9:1 molar ratio 
(acetic anhydride to HDA or HpDA) mixtures. 
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   Comparison of various molar ratios of acetic anhydride to HDA synthesized in acetonitrile or ethyl 
acetate is summarized in Figure 3.4.  The reaction conditions yielding >99% diacetyl-HDA was a 2:1 
molar ratio in acetonitrile (S5A) or a 4:1 molar ratio in ethyl acetate (S7E).  Reaction in ethyl acetate 
at molar ratio 0.9:1 (acetic anhydride to HDA) gave the maximum yield of monoacetyl-HDA (55%).  
Monoacetyl-HDA was quantified in the product by ascertaining the concentration of HDA and 
diacetyl-HDA in a known concentration of mixture against pure (≥99%) HDA and diacetyl-HDA 
standards.  Monoacetyl-HDA was quantified in these mixtures by subtracting out the known 
concentrations of HDA and diacetyl-HDA in the 1 mg/ml mixture quantified against pure (≥99%) 
HDA (0 – 1 µg/ml) and diacetyl-HDA standards (S7E; 0 – 4 µg/ml) prepared in ethyl acetate (R2 = 
0.999).  The limit of detection (LOD) of diacetyl-HDA in ethyl acetate, defined as a signal-to-noise 
ratio of 3, was 1 ng/ml, corresponding to 1 pg on-column injection.  The optimal reaction time 
resulting in both the maximum percent yield of monoacetyl-HDA and minimal percent of unreacted 
HDA was 2 h, which was also the reaction time used by Brorson and colleagues (1990)
21
.  These 
reaction conditions may also be used for the synthesis of monoacetyl-HDA and diacetyl-HpDA, used 
as the internal standard for monoacetyl-HDA and diacetyl-HDA quantification in biological samples. 
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B. Ethyl acetate 
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Figure 3.4 Relative percent abundance of HDA (♦),monoacetyl-HDA (■), and diacetyl-HDA 
(▲) in derivatized mixtures synthesized by varying the molar ratios of acetic 
anhydride to HDA (0.7:1 to 4:1) in acetonitrile (A) or ethyl acetate (B), reacting for 2 
h, drying filtrates under N2, and preparing 1 µg/ml solutions in ethyl acetate. 
 
3.4.2 Analysis of spiked urine.  GC-MS analysis of the spiked base-hydrolyzed urine revealed a 
chromatographic profile with a major peak at retention time of 16.1 min and containing an ion 
corresponding to monoderivatized monoacetyl-HDA, m/z 294 [M
-
-H3F3] eluting at 16.10 min (Figure 
62 
 
3.1B).  This major ion fragment stemmed from derivatized monoacetyl-HDA and whose acetyl group 
did not react with HFBA.  Furthermore, diacetyl-HDA in the base-hydrolyzed urine (spiked with S3E 
or S7E) was approximately 5 to 20-fold lower in sensitivity, revealing a limitation of base hydrolysis 
and subsequent HFBA derivatization for detection of both monoacetyl-HDA and diacetyl-HDA in 
biological samples.  The limit of detection (LOD; signal-to-noise of 3:1) and limit of quantification 
(LOQ; signal-to-noise of 10:1) for HDA, monoacetyl-HDA, and diacetyl-HDA in spiked urine 
subjected to no treatment or base hydrolysis are summarized in Table 3.1.  We postulated that base 
hydrolysis of urine modified the derivatization reaction of HFBA with the acetyl groups on 
monoacetyl-HDA and diacetyl-HDA.  It is unlikely that base hydrolysis converted diacetyl-HDA to 
monoacetyl-HDA or HDA since the chromatographic profiles of base-hydrolyzed urine samples 
spiked with pure diacetyl-HDA solution (S7E) did not show peaks corresponding to HDA or 
monoacetyl-HDA.  The lower sensitivity and different extraction method may explain why Brorson 
and colleagues (1990) did not detect diacetyl-HDA in base-hydrolyzed urine samples, while 
monoacetyl-HDA was detectable
21
.  Therefore, no hydrolysis treatment could be implemented to 
improve detection of diacetyl-HDA. 
 
Table 3.1 Summary of the LOD and LOQ values for HDA, monoacetyl-HDA, and diacetyl-
HDA in spiked urine under base hydrolysis or no treatment conditions. 
Analyte 
LOD (µg/l) LOQ (µg/l) 
Base hydrolysis No treatment Base hydrolysis No treatment 
HDA 0.035 0.030 0.12 0.10 
Monoacetyl-HDA 0.022 0.020 0.080 0.070 
Diacetyl-HDA 0.050 0.015 0.20 0.050 
LOD = limit of detection; LOQ = limit of quantification. 
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3.4.3 Analysis of urine samples.  Urine samples collected from three HDI exposed workers at the 
end of the workday were analyzed for HDA, monoacetyl-HDA, and diacetyl-HDA using base 
hydrolysis or no treatment.  The results are summarized in Table 3.2 along with HDI breathing-zone 
and dermal exposure levels as well as HDA concentrations analyzed in these same samples using 
acid-hydrolysis and published previously
41, 50, 53
.  All three untreated urine samples had detectable 
levels of diacetyl-HDA (0.015 – 0.062 µg/l) while one sample had a detectable level after base 
hydrolysis (0.065 µg/l).  Additionally, the signal-to-noise ratio of diacetyl-HDA in base-hydrolyzed 
samples was 2 to 10-fold lower compared to untreated samples.  Therefore, the sensitivity of diacetyl-
HDA analysis may be improved by not hydrolyzing the samples.  All three urine samples subjected to 
base hydrolysis had detectable levels of monoacetyl-HDA (0.19 – 2.2 µg/l) whereas monoacetyl-
HDA was detectable in two untreated samples (0.020 and 0.061 µg/l).  In addition, base-hydrolyzed 
samples had an average of 60-fold higher concentrations compared with the untreated samples.  These 
differences between untreated and base-hydrolyzed samples indicate the presence of monoacetyl-
HDA-protein adducts that are released after base-hydrolysis.  One urine sample had a detectable level 
of HDA after base hydrolysis (0.026 µg/l) while HDA was non-detectable in all untreated samples. 
 
Table 3.2 Summary of the inhalation and dermal HDI levels and HDA and acetylated HDA 
concentrations in the end-of-day urine samples collected from three workers 
occupationally exposed to HDI using different treatment conditions. 
Worker 
Breathing-
zone HDI
a
 
(µg/m
3
) 
Dermal 
HDI
b
 
(ng/mm
3
) 
HDA (µg/l) 
Monoacetyl-
HDA (µg/l) 
Diacetyl-HDA 
(µg/l) 
Acid
c
 Base None Base None Base None 
1 0.94 15.8 4.1 ND ND 1.7 0.020 ND 0.048 
2 15.0 730 10.1 0.026 ND 2.2 0.061 0.065 0.060 
3 4.3 20.3 0.36 ND ND 0.19 ND ND 0.015 
ND = non-detectable. 
a.
 Average HDI breathing-zone level across paint tasks (µg/m
3
) determined using LC-MS. 
b.
 Total dermal HDI exposure level across paint tasks (ng/mm
3
) determined using LC-MS. 
c.
 Urinary HDA concentration determined using acid hydrolysis and GC-MS
50
. 
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3.5 Discussion 
   Our analysis of monoacetyl-HDA and diacetyl-HDA in the urine of three HDI exposed workers 
adds to our understanding of an important metabolic pathway for HDI involving N-acetylation of 
HDA.  The difference in monoacetyl-HDA levels between untreated and base-hydrolyzed urine also 
demonstrates the presence of monoacetyl-HDA-protein adducts that are secreted into urine, and 
subsequently released with base hydrolysis.  The absence of HDA in untreated or base-hydrolyzed 
urine samples indicates that HDA is covalently bound to proteins, which was also demonstrated by 
Skarping and colleagues (1994)
45
.  Moreover, the concentration of bound monoacetyl-HDA (i.e., 
base-hydrolyzed minus untreated) in the urine samples represented 21 – 52% of the total HDA 
concentration (acid hydrolysis) while diacetyl-HDA represented 0.6 – 4% of the total HDA 
concentration indicating that monoacetyl-HDA adducts comprise a large portion of the total HDA 
with unbound diacetyl-HDA representing a minor component.  The concentration of total HDA in 
urine and HDI exposure levels followed a similar trend with monoacetyl-HDA and diacetyl-HDA 
(Table 3.2).  Further work analyzing these metabolites among a larger population of HDI exposed 
workers is needed to understand the significance of this metabolic pathway in the occupational 
setting.  We may integrate these findings for HDI metabolism with additional reaction pathways 
identified in other publications in our overview of HDI metabolism (Figure 1.1). 
   The identification of monoacetyl-HDA in individuals receiving HDA by oral administration also 
indicates the potential for N-acetylation metabolic pathway
21
.  However, prior to our study reported 
here, monoacetyl-HDA had not yet been identified in individuals exposed to HDI in the occupational 
setting where dermal and inhalation exposures are the major exposure routes.  Therefore, the 
identification and quantification of monoacetyl-HDA and diacetyl-HDA in urine of occupationally 
exposed workers demonstrates the relevance of the N-acetylation pathway in the metabolism of HDA.  
In addition, the difference in monoacetyl-HDA levels between base-hydrolyzed and untreated urine 
demonstrates the presence of monoacetyl-HDA-protein adducts that are secreted into urine. 
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   The association between HDI exposure and biomarker levels has been evaluated in several HDI 
exposure assessment studies and a good correlation between HDI inhalation exposure and urinary 
HDA levels has been observed
39, 43, 46, 47, 49
.  However, the impact of dermal exposure on urinary HDA 
levels has been quantitatively investigated in only one study
50
.  Investigation of these associations 
between exposure and biomarker levels has been hindered not only by the sensitivity of analytical 
methods, but also by the large inter- and intra-individual variability in plasma and urinary biomarker 
levels of HDA
39
.  In urine, this is partially attributed to the biphasic elimination pattern of HDA, 
characterized by a rapid elimination phase (t1/2 = 1.2 – 2.9 h) and a slow elimination phase, which 
may be attributed to the breakdown of HDI-protein conjugates in the blood
43, 46, 49
.  Furthermore, 
analyses of HDA in acid hydrolyzed urine may represent a combination of various metabolites, 
including free and protein conjugates of HDA and acetylated HDA.  Therefore, the identification of 
specific HDI metabolites, such as monoacetyl-HDA or diacetyl-HDA, would improve biological 
monitoring methods for HDI exposure by reducing the inter- and intra-individual variability in 
biomarker measures and providing further information on HDI metabolism. 
   The low proportion of diisocyanate-induced asthmatics with detectable specific IgE
7, 14
 has 
generated theories concerning disease mechanisms and genetic susceptibility.  Lung epithelial cells, 
such as keratin and serum albumin, can act as carriers (antigen presenting cells) that present HDI to 
the immune system, resulting in induction of mixed Th1/Th2 type response and lymphocyte 
production
4, 23, 25
.  Therefore, biomarker type and yield may be applied further to investigate metabolic 
pathways contributing to increased risk of diisocyanate-induced asthma.  Not only is the large inter-
individual variability in HDA levels partially attributed to workplace exposure factors, but also to 
individual differences in GST or acetylator status resulting from variable NAT enzyme activity that 
influence metabolism and susceptibility for disease
16
.  We have demonstrated the elimination of 
monoacetyl-HDA and diacetyl-HDA in the urine of occupationally exposed workers.  Factors driving 
these pathways may be further investigated using improved genotyping technologies for identifying 
individual single nucleotide polymorphisms and copy number variants affecting variable enzyme 
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activities.  Thus, analytical specificity for HDI biomarkers needs to be developed in order to 
investigate factors driving metabolic activation versus detoxification of HDI and susceptibility of 
diisocyanate-induced asthma. 
   Our analysis of monoacetyl-HDA and diacetyl-HDA in the urine samples collected from 
occupationally exposed workers demonstrates the relevance of the N-acetylation metabolic pathway 
for HDI following exposure.  Our proposed analytical methods for the quantification of monoacetyl-
HDA and diacetyl-HDA in untreated or base-hydrolyzed urine may be utilized and applied to further 
investigate individual differences in HDI metabolism and relate these measurements to HDI exposure 
levels and susceptibility factors for HDI-associated diseases. 
 
3.6 Conclusions 
   Highly sensitive and specific analytical methods for HDI biomarkers would allow for improved 
characterization of HDI exposure patterns and predicting systemic exposure and dose, as well as 
enhance our understanding of exposure-disease relationships.  Progress has been made in identifying 
HDI metabolic pathways and intermediates leading to the formation of various protein adducts that 
may play a role in disease development.  However, further research is needed to improve the 
sensitivity and specificity of analytical methods for the detection of HDA and other metabolites to 
better explain the sources of intra- and inter-individual variability in metabolite formation related to 
HDI exposure.  The lack of commercially available analytical standards for monoacetyl-HDA and 
diacetyl-HDA has also hindered quantification of these metabolic products in biological samples.  
Therefore, we have optimized the reaction conditions for monoacetyl-HDA and diacetyl-HDA 
synthesis and presented analytical methods for their analysis in order to improve quantification of 
these metabolites in biological samples.  In addition, we have demonstrated that monoacetyl-HDA 
and diacetyl-HDA may be quantified in the urine of exposed workers, thereby further contributing to 
our understanding of HDI metabolism.
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4.1 Abstract 
   We investigated the utility of 1,6-hexamethylene diamine (HDA) hemoglobin adducts as 
biomarkers of exposure to 1,6-hexamethylene diisocyanate (HDI) monomer.  Here, we describe the 
hemoglobin (Hb) analysis of HDA (HDA-Hb), N-acetyl-1,6-hexamethylene diamine (monoacetyl-
HDA-Hb), and N,N’-diacetyl-1,6-hexamethylene diamine (diacetyl-HDA-Hb) in 15 spray painters (N 
= 35) applying HDI-containing paint in vehicle repair shops.  These biomarkers were detected by GC-
MS as heptafluorobutyryl derivatives in base-treated Hb.  HDA-Hb was quantified in all workers 
(≤1.2 – 37 ng/g Hb).  Monoacetyl-HDA-Hb was detected in one worker (0.06 ng/g Hb) while 
diacetyl-HDA-Hb was not detected in any of the workers.  There was a stronger, positive association 
between HDA-Hb adduct concentration and cumulative HDI dermal (r
2
 = 0.32, p = 0.058), inhalation 
(r
2
 = 0.35, p = 0.042), and air (r
2
 = 0.34, p = 0.048) exposure than the same day exposure levels (p ≥ 
0.13).  In addition, there was a strong, inverse association between HDA concentration in acid-
hydrolyzed urine and cumulative HDA-Hb adduct (r
2
 = 0.28 – 0.32, p = 0.06-0.08) or total plasma 
HDA (r
2
 = 0.21, p = 0.13) concentration.  The association between HDA-Hb adduct and plasma HDA 
concentration within the same blood sample was weak (r
2
 = 0.039, p = 0.38).  These findings indicate 
long-term elimination kinetics for HDA-Hb adducts and, potentially, competing HDI metabolic 
pathways.  These findings on the type and yield of different HDA blood biomarkers, and their 
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association with urine HDA concentration and HDI dermal and inhalation exposure, indicate that 
these biomarkers are suitable for further validation as biomarkers of exposure and for characterization 
of HDI-specific metabolic pathways that may contribute to disease susceptibility. 
 
4.2 Environmental Impact Statement 
   While exposure to HDI monomer has been linked with occupational asthma, few studies have 
quantitatively investigated the association between HDI exposure and blood biomarker levels in the 
occupational setting.  These biomarkers may be important indicators of cumulative exposure as a 
result of the formation of long-lived protein adducts during HDI metabolism.  We were able to 
measure HDI-specific hemoglobin adducts in workers exposed to HDI and demonstrate their potential 
use as biomarkers of indicated cumulative exposure to HDI. 
 
4.3 Introduction 
   1,6-hexamethylene diamine (HDA) in biological media (e.g., urine, plasma) has been utilized as a 
biological marker for 1,6-hexamethylene diisocyanate (HDI) exposure
39, 43, 45-51
.  During automotive 
spray-painting, workers are exposed to HDI present in paint formulations via skin or inhalation 
routes.  In biological samples these markers represent the integration of HDI exposure across multiple 
exposure routes.  Repeated or prolonged exposure to HDI may also result in skin or respiratory 
sensitization
7, 54 
and development of occupational asthma
5, 6
.  Trace amounts of HDI monomer and 
larger amounts of HDI oligomer (e.g., uretdione, biuret, and isocyanurate) as vapors and/or aerosols 
are produced during painting with isocyanate containing paints
2, 3, 39, 76
.  Repeated skin exposure at 
these trace levels to HDI monomer (0.1%) may cause skin sensitization, which can develop into 
asthma following inhalation exposure to HDI monomer
4
.  Therefore, characterizing and quantifying 
biomarkers of HDI monomer exposure continues to be critical in evaluating workplace exposure, 
developing strategies for mitigating exposure, and preventing adverse health effects. 
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   HDA in acid-hydrolyzed urine and plasma are the only validated biomarkers to date for short-
term
46, 47, 50 
and cumulative exposure to HDI monomer
51
.  Once in the body, the isocyanato moiety 
(NCO) may be hydrolyzed to an amine (e.g. HDA), catalyzed by bicarbonate in the blood
57
, or react 
with proteins, such as albumin and hemoglobin (Hb), to form protein adducts.  HDA could be N-
acetylated by N-acetyltransferase (NAT) to form monoacetyl-HDA
21
 and diacetyl-HDA and/or 
undergo N-oxidation by cytochrome P450 (CYP450) or a flavine adenine dinucleotide (FAD)-
dependent enzyme system
20
 and further oxidized to form a nitroso compound
19
.  The oxidation 
pathway would eventually result in the formation of amine-derived protein adducts, persisting over 
the half-life of albumin (t1/2 = 19 days)
77
 or the life-span of Hb (120 days)
78
.  Individual differences in 
acetylator genotype (fast vs. slow) that drive these dominant metabolic pathways have been linked 
with asthma risk
16
.  Protein adducts are also formed via hydrolysis of bis-thiocarbamate intermediates 
resulting from the reaction of NCO with thiols, such as cysteine
18
.  Different protein adducts or 
metabolites formed from these various non-enzymatic- or enzymatic-directed pathways following 
HDI monomer exposure have not been fully characterized in exposed individuals.  Such information 
would help to identify important metabolic intermediates that are indicators of individual 
susceptibility for asthma and other health effects. 
   The main advantage in measuring blood biomarkers of HDI exposure is to obtain internal dose 
measures of cumulative exposures due to the formation of long-lived protein adducts.  The stronger 
correlation between HDA in acid-hydrolyzed plasma and dermal or inhalation exposure to HDI 
monomer occurring ~0.5 – 2 months before blood collection compared with the same-day exposure 
among 46 spray painters demonstrated the presence of longer-lived albumin adducts
51
.  Moreover, a 
biphasic elimination pattern has been described for diisocyanate-derived amines, thought to result 
from the rapid urinary excretion of short-term metabolites within a few hours
43, 46
, followed by the 
excretion of long-lived protein adducts days later
58
. The presence of HDA in the majority of first-day, 
pre-exposure urine samples among HDI exposed spray painters, also indicated the slow elimination of 
protein conjugates accumulated during the work-week
50
.  In addition to being an indicator of past 
70 
 
exposure to diisocyanates, protein adducts may contribute to the pathogenesis of diisocyanate-
induced asthma by their action as protein carriers in presenting HDI to the immune system
23
.  
Therefore, the correlation between HDA-protein adducts in blood and HDI exposure levels or urine 
biomarkers would provide additional information on the uptake and elimination kinetics of HDI 
metabolites and, thus, the biological availability of these reaction products in contributing to disease 
development.   
   The presence of Hb adducts may indicate cumulative exposure across a more extensive period of 
time (≤120 days) compared with albumin adducts (≤60 days) or free HDA (several hours).  A benefit 
of Hb adduct analysis is the enhanced specificity compared with HDA analysis using acid-hydrolysis.  
Measured HDA from acid-hydrolyzed plasma (i.e., plasma HDA) or urine (i.e., urine HDA) may be 
derived from both unbound and protein-conjugated HDA, monoacetyl-HDA, and diacetyl-HDA
79
.  
Acid treatment of plasma or urine masks individual variability in the types and yield of various 
metabolites which, in turn, could provide information about susceptibility factors and mechanisms 
related to disease development.  Hb isolation followed by mild base treatment, has resulted in the 
identification of 4,4’-methylene dianiline (MDA) and monoacetyl-MDA adducts19, and these methods 
could be applied to blood samples for identifying HDA-Hb and monoacetyl-HDA-Hb adducts.   
   The mechanism by which reactive diisocyanates are transported across the epithelial layer of the 
respiratory tract, into the blood, and through the erythrocyte membrane to react with Hb is unknown, 
but may involve the formation of mono- and bis-thiocarbamate intermediates
18
.  Such products 
formed by the reaction of diisocyanate with cysteine would allow transport across cellular 
membranes.  Chipinda and colleagues postulated that the bis-thiocarbamate product could be carried 
from the lung to a distal site, whereupon hydrolysis would occur, releasing a free diisocyanate that 
could react with another nucleophile
18
.  Because the rates of hydrolysis among the different 
diisocyanate intermediates vary widely, the biological availability of reactive intermediates may also 
vary.  Thus, investigation of HDA-Hb adducts would provide important information on potential 
metabolic pathways and reaction products related to diisocyanate-mediated hypersensitivity diseases.  
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   There are no publications reporting the proportion of Hb to albumin adducts resulting from HDI 
exposure and how these protein adduct concentrations vary with urine HDA concentration.  Sepai and 
colleagues reported that MDA was detected as Hb adducts in all 20 exposed workers to 4,4’-
methylene diphenyl diisocyanate (MDI), and monoacetyl-MDA was detected as a Hb adduct in 1 
worker
19
.  However, the albumin adduct levels were 450-fold higher than the Hb adduct levels.  
Whether albumin adducts are also the dominant products formed from HDI exposure has yet to be 
investigated.  Pauluhn and colleagues observed different levels of Hb adducts and urinary MDA 
corresponding to MDI or MDA exposure and varying MDA-Hb levels by exposure route (i.e., dermal 
or inhalation)
56
.  In our previous study, plasma HDA levels were modified by coverall use and type of 
ventilated paint booth that the workers used during spray painting
51
. Therefore, exposure route, 
stability of metabolic intermediates, and exposure to the diisocyanate versus the diamine (e.g., HDI 
vs. HDA) may drive specific metabolic pathways of HDI and, consequently, the types and yields of 
products formed. 
   The objectives of this study were to: (i) quantify Hb adducts of HDA, monoacetyl-HDA, and 
diacetyl-HDA resulting from HDI exposure, using mild base treatment, in 15 exposed spray painters, 
(ii) investigate these measures as biomarkers of short- or long-term HDI exposure by correlating 
plasma HDA or Hb adduct concentrations with same day or cumulative HDI monomer air, dermal, or 
inhalation exposures, and (iii) compare elimination kinetics of Hb adducts and plasma HDA by 
correlating these concentrations with urine HDA concentration in acid-treated samples (pre-shift, 
post-shift, daily average). 
 
4.4 Materials and Methods 
4.4.1 Chemicals 
Solvents and chemicals purchased from Thermo Fisher (Hampton, NH): HPLC grade (99.9%) 
dichloromethane (#AC61005–0040), ethyl acetate (#AC61006–0040), acetonitrile (#AC61001–0040), 
sodium sulfate anhydrous (certified ACS, #S421–500), acetic anhydride (>99%, #AC14949–0010), 
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sodium hydroxide (certified ACS, #S318–500), and hemoglobin (#ICN10071425); and from Sigma 
Aldrich (St. Louis, MO): 1,6–hexamethylene diamine (≥99%, #33000), 1,7–diaminoheptane (98%, 
#D17408), and heptafluorobutyric anhydride (derivatization grade, #394912). 
 
4.4.2 Synthesis of standards 
4.4.2.1 Preparation of HDA and acetylated HDA (standards).  A standard mixture of HDA, 
monoacetyl-HDA and diacetyl-HDA was prepared by making a 2 mg/ml solution of HDA in ethyl 
acetate (50 ml total volume).  Acetic anhydride was added dropwise at 0.9:1 molar ratio (acetic 
anhydride to HDA) with constant stirring at room temperature.  The solution was allowed to react for 
2 h and was subsequently filtered under vacuum using a 0.22 µm, 25 mm nylon filter.  A portion of 
the filtrate was dried under nitrogen and a 1 mg/ml solution of the dried product prepared in ethyl 
acetate, and stored at 4ºC. 
 
4.4.2.2 Synthesis of diacetyl-HDA (≥99%).  A solution of diacetyl-HDA (≥ 99%) was synthesized by 
preparing a 2 mg/ml solution of HDA in ethyl acetate (50 ml total volume).  Acetic anhydride was 
added dropwise at 4:1 molar ratio (acetic anhydride to HDA) with constant stirring at room 
temperature.  The solution was allowed to react for 2 h and was subsequently filtered under vacuum 
using a 0.22 µm, 25 mm nylon filter.  A portion of the filtrate was dried under nitrogen and a 1 mg/ml 
solution of the dried product prepared in ethyl acetate and stored at 4ºC. 
 
4.4.2.3 Preparation of HpDA and acetylated HpDA (internal standards).  An internal standard (IS) 
mixture of 1,7-diaminoheptane (HpDA), monoacetyl-HpDA and diacetyl-HpDA was prepared by 
making a 2 mg/ml solution of HpDA in ethyl acetate (50 ml total volume).   Acetic anhydride was 
added dropwise at 0.9:1 molar ratio (acetic anhydride to HpDA) with constant stirring at room 
temperature.  The solution was allowed to react for 2 h and was subsequently filtered under vacuum 
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using a 0.22 µm, 25 mm nylon filter.  A portion of the filtrate was dried under nitrogen and a 1 mg/ml 
solution of the dried product prepared in ethyl acetate, and stored at 4ºC. 
 
4.4.2.4 Preparation of HDA and diacetyl-HDA standard curves. To quantify HDA, monoacetyl-
HDA, and diacetyl-HDA in the standard mixture, HDA and diacetyl-HDA standard curves were 
prepared in ethyl acetate.  First, HDA and IS solutions (1 µg/ml) were prepared.  A 5 µg/ml solution 
of diacetyl-HDA was prepared in ethyl acetate.   A 1:1 serial dilution (1 ml total volume) of HDA and 
diacetyl-HDA solutions (in duplicate) was performed in ethyl acetate to obtain a concentration range:  
HDA (0 – 1 µg/ml) and diacetyl-HDA (0 – 5 µg/ml).  Each diluted sample of HDA or diacetyl-HDA 
was spiked with 100 µl of 1 µg/ml IS mixture (final concentration = 0.1 µg/ml).  Diluted standard 
mixture solutions (5 µg/ml) were prepared in ethyl acetate (1 ml total volume) and spiked with 100 µl 
of 1 µg/ml IS mixture.  Solutions were reacted with 10 µl HFBA for 1 h at 55ºC and immediately 
analyzed by gas chromatography-mass spectrometry (GC–MS).   
 
4.4.3 Analysis and work-up procedures 
4.4.3.1 GC-MS analysis.  Samples were analyzed by GC-MS (Thermo Trace GC Ultra interfaced 
with a PolarisQ ion trap mass spectrometer and AI/AS 3000 injector, and Xcalibur 1.4 SR1 software, 
Thermo Electron Corporation, Austin, TX).  Injections (1 µl) were made under splitless mode of 30 s 
with injector temperature of 220ºC.  Separation of the samples was carried out with a GC capillary 
column (DB5-MS, 30 m  0.25 mm ID, 0.1 µm film thickness; Agilent Technologies, Palo Alto, CA).  
The ion source and GC transfer line temperatures were maintained at 150ºC and 260ºC, respectively.  
Helium was used as the carrier gas with a constant flow of 1 ml/min.  The GC oven temperature 
program was 50ºC (1.0 min) to 155ºC at 10ºC/min, 155ºC to 185ºC at 2ºC/min, and 185ºC to 300ºC at 
25ºC/min (final temperature held for 10 min).  Ions were monitored in negative ion chemical 
ionization mode using methane as the reagent gas (1.8 ml/min).  Mass spectra were acquired in the 
mass-to-charge ratio (m/z) range 200 – 600.   
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   GC-MS analysis of the standard curves and standard mixture revealed that the major ions 
corresponding to derivatized HDA, monoacetyl-HDA, and diacetyl-HDA were m/z 448 [M–H3F3]
–
 
eluting at 14.1 min, 510 [M–H2F2]
–
 eluting at 15.1 min, and 552 [M–H2F2]
–
 eluting at 16.2 min, 
respectively (Figure 1).  The major ion for HpDA, monoacetyl-HpDA, and diacetyl-HpDA in IS 
mixture was m/z 462 [M–H3F3]
–
 eluting at 15.6 min, 524 [M
––H2F2]
–
 eluting at 16.6 min, and 566 
[M–H2F2]
–
 eluting at 17.7 min, respectively.  The mass spectra for each corresponding standard peak 
reflected successive losses of hydrogen (H) and fluorine (F) atoms from derivatized parent amines 
(HDA = 508, monoacetyl-HDA = 550, diacetyl-HDA = 592 g/mol) and internal standard amines 
(HpDA = 522, monoacetyl-HpDA = 564, diacetyl-HpDA = 606 g/mol).  Ion selection used in 
quantification of each amine was based on the most abundant ion fragment in mass spectra.   
 
Figure 4.1 GC-MS chromatogram of various amines extracted from base-treated Hb solution (50 
mg/ml) spiked with standard mixture (per mg Hb:  0.010 µg HDA, 0.11 µg 
monoacetyl-HDA, 0.14 µg diacetyl-HDA) and IS mixture (0.50 µg/mg Hb) with the 
corresponding major fragment ion (m/z). 
 
4.4.3.2 Quantification of HDA and acetylated HDA in mixture.  Peaks corresponding to HDA and 
acetylated HDA, as well as HpDA and acetylated HpDA were integrated.  Quantification of HDA and 
HpDA 
HDA 
monoacetyl-HDA 
diacetyl-HDA 
monoacetyl-HpDA 
diacetyl-HpDA 
448 
510 
552 
462 
524 
566 
m/z 
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diacetyl-HDA in the standard mixture was performed using a linear calibration graph of peak-area 
response of HDA to peak-area response of HpDA in calibration standards (r
2
 = 0.999) and a graph of 
peak-area response of diacetyl-HDA to peak-area response of diacetyl-HpDA in calibration standards 
(r
2
 = 0.998), respectively.  The concentration of monoacetyl-HDA was calculated by subtracting the 
known concentration of HDA and diacetyl-HDA from the total concentration (5 µg/ml).  The 
standard mixture yielded 0.09 µg/ml HDA (1.8%), 2.11 µg/ml monoacetyl-HDA (55.7%), and 2.80 
µg/ml diacetyl-HDA (42.5%). 
 
4.4.3.3  Biomarker and exposure measurements.  Fifteen spray painters (4 from North Carolina and 
11 from Washington State) were randomly selected from our larger HDI study population (n = 46) 
reported previously
51
.  Blood samples were collected during each sampling visit when workers 
consented (N = 35).  Six workers were sampled twice, and eight workers were sampled three times.  
Blood was collected in EDTA and heparin tubes at the end of the workday and plasma separated 
within 48 h of collection.  After the plasma and red blood cells were isolated, samples were stored at 
–35ºC until analyzed.  Urine was collected throughout the workday, and stored at –35°C until 
analyzed.  Analyses for urine and plasma HDA in acid-hydrolyzed samples have been published 
elsewhere
50, 51
.  Briefly, 1 ml of urine or plasma (in duplicate), containing 100 µl sulfuric acid and 
HpDA internal standard, was baked at 100°C for 16 h.  HDA was extracted 3 times into 2 ml toluene, 
pooled extracts derivatized with 20 µl HFBA at 55°C for 1 h, and dried under nitrogen.  Samples 
were reconstituted into 60 µl ethyl acetate and analyzed by GC-MS. 
   Breathing-zone and dermal exposure measurements among these occupationally exposed spray 
painters have been published elsewhere
41, 53.  Briefly, a personal air sample in the worker’s breathing-
zone was collected during each spray-painting operation of clear-coat using a 1-stage or 2-stage filter 
sampling system housed in a 37-mm polystyrene cassette (SKC Inc., Eighty Four, PA, USA) attached 
to a high-flow air pump operating at 1.0 l/min (SKC).  The 2-stage sampler used in this study 
contained an untreated polytetrafluoroethylene pre-filter (designed to collect diisocyanate aerosols) 
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and a glass-fiber filter impregnated with derivatizing agent (designed to collect and derivatize 
diisocyanate vapors).  The 1-stage sampler was identical to the 2-stage sampler except that the pre-
filter was not included in the cassette.  Among visits where 1- and 2-stage air samplers were used 
side-by-side (n = 1), we selected 1-stage air data for regression and statistical analyses based on 
findings by Fent and colleagues
53
.  Air and skin samples were analyzed by LC-MS as previously 
described by Fent and colleagues
41, 53.  Work diaries and questionnaires about workers’ physical 
characteristics (e.g., age, height, weight), type and frequency of PPE use (e.g., coveralls, respirator, 
gloves), and work environment (e.g., paint booth type, duration of paint tasks) were completed during 
each visit. 
 
4.4.3.4 Work-up procedure for Hb adducts.  The sample work-up procedure was adapted from a 
previously published method describing the analysis of Hb adducts of MDA and monoacetylated 
MDA
19
.  The separated red blood cells (4 ml) were removed from –35ºC storage and sat at room 
temperature until thawed (~30 min).  The Hb was precipitated from the lysate with 20 ml ethanol and 
centrifuged (4000 g, 10 min).  The precipitate was washed with a series of organic solvents (20 ml 
each of 1:1 ethanol: water, ethanol, 4:1 diethyl ether: ethanol, and diethyl ether), with centrifuging 
between each wash.  The Hb was dried in a dessicator at 4°C overnight.   
   Portions (200 mg) of Hb were dissolved in 4 ml sodium hydroxide (0.1 M) in the presence of IS 
mixture (final concentration 5 ng/g Hb).  After 60 min at room temperature, the amines were 
extracted (2x) from basic solution into 6 ml dicholoromethane, vortexed for 2 min, and then 
centrifuged for 10 min at 1000 g.  To achieve optimal separation, samples were frozen at –35ºC and 
then allowed to thaw at room temperature.  The pooled extracts were dried over sodium sulfate and 
derivatized with 10 µl HFBA.  After 30 min at room temperature, the samples were dried under 
nitrogen using a TurboVap
®
 LV Evaporator (Zymark Center; Hopkinton, MA).  The dried residues 
were dissolved in 200 µl ethyl acetate and placed in an ultrasonic bath for several minutes.  The 
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sample solutions were transferred to GC vial inserts and evaporated to dryness using a SpeedVac
®
 
(Savant Instruments Inc., Holbrook, New York).  The dried residues were dissolved in 60 µl ethyl 
acetate.  One reagent blank and two calibration standards were prepared with every set of Hb samples 
collected from the workers.  The samples were analyzed by GC-MS as described above. 
 
4.4.3.5 Standard curve preparation for Hb adduct analysis.  A 50 mg/ml solution of Hb was 
prepared in 0.1 M sodium hydroxide (100 ml total volume).  Portions (4 ml, in duplicate) of Hb 
solution were spiked with HDA and acetylated HDA mixture to make concentration range (N = 7, in 
duplicate):  HDA (0 – 0.045 ng/mg Hb), monoacetyl-HDA (0–1.05 ng/mg Hb), and diacetyl-HDA (0 
– 1.40 ng/mg Hb).  Each sample was spiked with internal standard mixture (final concentration 5 
pg/mg Hb).  Each calibration sample was treated according to procedure for Hb-adduct analysis.  
Samples were analyzed by GC-MS according to the above procedure.  The limit of detection (LOD) 
for HDA, monoacetyl-HDA, and diacetyl-HDA was 1.2 ng/g Hb, 0.03 ng/g Hb, and 0.05 ng/g Hb.   
 
4.4.4 Variable construction.   
   The breathing-zone concentration (BZC) of HDI monomer for each paint task (µg/m
3
) was 
multiplied by the total paint time (min) for each task and summed together to obtain a daily air 
exposure level (µg/m
3
 × min).  To obtain a daily inhalation exposure level (µg/m
3
 × min) the BZC 
was divided by the OSHA Assigned Protection Factor (APF) based on respirator type
69
: none, APF = 
1; air purifying (half face), APF = 10; air purifying (full facepiece), APF = 50; supplied air (full 
facepiece or hood), APF = 1000; PAPR (full facepiece or hood), APF = 1000.  The dermal 
concentration from tape-strips (ng/mm
3
) were summed together for each task, and the task-based 
dermal values were summed together to obtain a daily dermal exposure level (ng/mm
3
).  HDA 
concentration in the pre-shift (i.e., beginning of day) urine sample, post-shift (i.e., end of day) urine 
sample, as well as daily total urine HDA concentration (ng/ml) was used in the data analysis.  The 
concentration of Hb adducts (ng/g Hb), and plasma HDA (ng/ml) were used in the data analysis. 
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4.4.5 Statistical analysis.   
   The percent coefficient of variation (CV) was calculated for Hb adduct analysis among replicate 
samples. The correlation between Hb adducts and plasma or urine HDA and between Hb adducts and 
HDI air exposure was investigated using linear regression analysis (PROC REG procedure in SAS, 
version 9.1; SAS Institute, Cary, NC), with a significance level of 0.10.  For regression and summary 
statistics all variables were natural log-transformed to meet the assumption of normality (Shapiro-
Wilk W > 0.80).  For all biomarker or exposure concentrations below the LOD, values of LOD/√2 
were imputed. 
   Because plasma albumin has a circulating serum half-life of 19 days and hemoglobin has a lifespan 
of 120 days we selected a time frame of 0 to 4 months to investigate the associations between the 
blood biomarker concentration in plasma or Hb and cumulative HDI air or dermal exposure.  This 4-
month time frame would correspond to ~98% loss of HDA-albumin adducts and ~100% loss of 
HDA-Hb adducts resulting from HDI exposure.  This time frame was also used to investigate the 
association between cumulative blood biomarkers and HDA concentration in urine.  These 
cumulative exposure estimates were obtained by summing the daily HDI air or dermal concentrations 
across all repeated sampling visits for each worker.  The cumulative blood biomarker estimates were 
obtained by summing the plasma HDA or HDA-Hb adduct concentrations across all repeated 
sampling visits for each worker.  We investigated the associations between HDI exposure or urine 
HDA and blood HDA biomarkers among workers sampled on two or three repeated visits. 
 
4.5 Results 
 
4.5.1 Biomarker and exposure concentrations in occupationally exposed workers. 
   The range of HDA-Hb adduct concentrations among NC workers (n = 4) was 1.3 – 6.6 ng/g Hb and 
among WA workers (n = 11) was ≤1.2 – 37 ng/g Hb.  The majority of samples were above the LOD 
(95%) for HDA-Hb concentration.  Monoacetyl-HDA-Hb was detected in one worker (0.06 ng/g Hb), 
and diacetyl-HDA was not detected in any of the workers.  The CV among replicate Hb samples was 
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in the range of 1 – 20%, which is similar to those reported for plasma HDA, while spiked standards 
were in the range of 1 – 10%.  The lower quantitative precision among Hb samples compared with 
spiked standards may be attributed to the release of amines from biological matrices affecting the 
variation in recovered amines from Hb conjugates. 
   The range of HDA in base-treated Hb (N = 35) was ≤1.2 – 37, and in acid-hydrolyzed plasma (N = 
35) was ≤0.02 – 0.71 ng/ml (Table 4.1).  The majority of plasma samples (~90%) were ≥LOD for 
HDA.  The average and standard deviation for HDA-Hb adduct and plasma HDA concentrations in 
each worker are provided in Figure 4.2, which depicts the large within-worker variability in 
biomarker levels and the weak association between these biomarker types.  The within-worker 
variability (>90%) comprised a greater portion of the total variability in both HDA-Hb adduct and 
plasma HDA concentration.  The range of HDA concentrations in acid-hydrolyzed urine was ≤0.03 – 
66 µg/l (N = 116; Table 4.1). All breathing-zone concentrations were greater than the LOD while 
40% of dermal exposure concentrations by paint task were ≥LOD.  The HDI monomer dermal 
exposure range was 2.0 – 38,100 ng/mm3, inhalation exposure range was 0.034 – 864 µg/m3 × min, 
and air exposure range was 0.25 – 2,570 µg/m3 × min (N = 35; Table 4.1). 
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Table 4.1 Summary of the measured HDA-Hb adduct (ng/g Hb), plasma HDA (ng/ml), and 
urine HDA (ng/ml) concentrations as well as HDI dermal (ng/mm
3
), inhalation 
(µg/m
3
 × min), and air (µg/m
3
 × min) exposure among 15 automotive spray painters. 
Sample n N GM GSD Range 
HDA-Hb 15 35 3.0 2.0 1.3 – 37 
      
Plasma HDA 15 35 0.061 2.7 0.012 – 0.71 
      
Urine HDA      
pre-shift 15 35 0.18 5.0 0.021 – 7.8 
post-shift 15 35 0.25 5.6 0.021 – 66 
all samples 15 116 0.22 4.5 0.021 – 66 
      
HDI dermal exposure
a
 15 35 131 7.1 2.0 – 38,100 
HDI inhalation exposure
b
 15 35 7.8 11.0 0.034 – 864 
HDI air exposure
c
 15 35 72 6.1 0.25 – 2,570 
GM, geometric mean; GSD, geometric standard deviation; n, number of workers; N, number of 
samples 
a. ∑nj=1 (HDI dermal exposure)j; Sum of HDI dermal concentration across all daily tasks (j) was 
obtained by calculating the sum of the dermal concentration measured for each task and then 
summing the task-based dermal values. 
b. ∑nj=1 (HDI inhalation exposure)j; Sum of HDI inhalation concentration across all daily tasks (j) 
was obtained by dividing the measured breathing-zone concentration by the OSHA Assigned 
Protection Factor (APF) based on respirator type for each task and then summing the task-based 
inhalation values. 
c. ∑nj=1 (HDI air exposure)j; Sum of HDI air concentration across all daily tasks (j) was obtained by 
multiplying the measured breathing-zone concentration for each paint task (µg/m
3
) by the paint 
time (min) for each task and then summing the task-based air values. 
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Figure 4.2 Average HDA-Hb adduct (ng/g) and plasma HDA levels (ng/ml) in each worker (n = 
15). 
 
 
4.5.1.1 Blood biomarker concentration vs. HDI exposure.  Table 4.2 summarizes the regression 
analysis of Hb-adduct or plasma HDA concentration versus same day or cumulative HDI dermal, 
inhalation, or air exposure.  The positive association between HDA-Hb adduct concentration and HDI 
exposure was strongest with cumulative dermal (N = 12, r
2
 = 0.32, p = 0.058), cumulative inhalation 
(N = 12, r
2
 = 0.35, p = 0.042), or cumulative air exposure (N = 12, r
2
 = 0.34, p = 0.048).  The 
association between plasma HDA concentration and HDI exposure was strongest with cumulative 
inhalation (N = 12, r
2
 = 0.32, p = 0.023) or cumulative air exposure (N = 12, r
2
 = 0.37, p = 0.036), 
similar to previous findings reported for the entire study population (n = 46) which reported stronger 
associations with past HDI exposure levels
9
.  However, plasma HDA was negatively associated with 
the same day or cumulative HDI exposures among these workers.  These different time-dependent 
associations (i.e., same day or cumulative) between HDI air or dermal exposure and plasma HDA or 
HDA-Hb concentration may be attributed to the half-life of albumin (t1/2 = 19 days) and Hb lifespan 
(120 days), respectively. 
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Table 4.2 Log-transformed HDA-Hb adduct (ng/g Hb) or plasma HDA (ng/ml)  concentration 
on last sampling visit versus the log-transformed same day or cumulative HDI dermal 
(ng/mm
3
), inhalation (µg/m
3
 × min), or air (µg/m
3
 × min) exposure among workers 
sampled two (n = 4) or three times (n = 8). 
 
Exposure Route 
Time of HDI 
exposure
a
 
Blood HDA n N r
2
 p-value
b
 
Association 
(+/-)
c
 
Dermal same day Hb 12 12 0.15 0.206 + 
   Plasma 12 12 0.033 0.571 - 
 cumulative  Hb 12 12 0.32 0.058 + 
    Plasma 12 12 0.13 0.255 - 
Inhalation same day Hb 12 12 0.22 0.126 + 
   Plasma 12 12 0.36 0.041 - 
 cumulative Hb 12 12 0.35 0.042 + 
    Plasma 12 12 0.42 0.023 - 
Air same day Hb 12 12 0.18 0.173 + 
   Plasma 12 12 0.20 0.150 - 
 cumulative Hb 12 12 0.34 0.048 + 
    Plasma 12 12 0.37 0.036 - 
n, number of workers; N, number of values 
a.
 Same day or cumulative HDI exposure. 
b.
 p-value determined using linear regression analysis; significant associations (p ≤ 0.10) are bolded. 
c.
 Positive (+) or negative (-) association between HDI exposure and blood HDA biomarkers. 
 
4.5.1.2 Urine HDA concentration vs. blood biomarker concentration.  The association between 
HDA-Hb adduct and plasma HDA concentrations in the same blood sample was weak (N=35, r
2
 = 
0.039, p = 0.38).  Table 4.3 summarizes the correlations between HDA concentration in pre-shift, 
post-shift, or daily average urine sample versus HDA-Hb adduct or plasma HDA concentration in 
blood samples collected on the same day or cumulative blood HDA concentration.  Urine HDA 
concentration was more strongly correlated with cumulative HDA-Hb adduct (r
2
 = 0.28-0.32, p = 
0.055-0.080) or plasma HDA concentration (r
2
 = 0.21, p = 0.13) compared to the same day blood 
concentrations (Table 3).  There was a positive association between HDA concentration in urine 
sample (pre-shift, post-shift, or total HDA) and plasma HDA measured on the same day, while there 
was a negative association between urine HDA concentration and cumulative plasma HDA 
concentration.  Of the different urine samples collected during the workday (i.e., pre-shift, post-shift, 
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total HDA), the total daily urine HDA concentration was most strongly correlated with cumulative 
plasma HDA (N = 12, r
2
 = 0.21, p = 0.13).  There was no association between urine HDA and the 
same day HDA-Hb adduct concentration, while there was a strong, negative association between 
urine HDA (pre-shift, post-shift, and total HDA) and cumulative HDA-Hb adduct concentration. 
 
Table 4.3 Log-transformed HDA concentration (ng/ml) in urine (pre-shift, post-shift, or daily 
total HDA) from last sampling visit versus the log-transformed same day or 
cumulative HDA-Hb adduct (ng/g Hb) or plasma HDA (ng/ml) concentration among 
workers sampled two (n = 4) or three times (n = 8). 
 
Blood 
samples
a
 
HDA in urine 
sample(s)
b
 
Blood HDA
c
 n N r
2
 p-value
d
 
Association 
(+/-)
e
 
same day pre-shift Hb 12 12 0.003 0.859 NA 
   Plasma 12 12 0.16 0.191 + 
 post-shift Hb 12 12 0.001 0.938 NA 
   Plasma 12 12 0.13 0.249 + 
 total Hb 12 12 0.005 0.831 NA 
    Plasma 12 12 0.075 0.389 + 
cumulative pre-shift Hb 12 12 0.32 0.056 - 
   Plasma 12 12 0.19 0.152 - 
 post-shift Hb 12 12 0.32 0.055 - 
   Plasma 12 12 0.11 0.285 - 
 total Hb 12 12 0.28 0.080 - 
    Plasma 12 12 0.21 0.133 - 
n, number of workers; N, number of values; NA, no association 
a.
 Same day or cumulative (i.e., 0 – 4 months) HDI exposure. 
b.
 Dependent variable 
c.
 Independent variable. 
d.
 p–value determined using linear regression analysis; significant associations (p ≤ 0.10) are bolded. 
e.
 Positive (+) or negative (-) association between urine HDA and blood HDA biomarkers. 
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4.6 Discussion 
   We developed a method to measure HDA-Hb, monoacetyl-HDA-Hb, and diacetyl-HDA-Hb 
adducts as biomarkers of HDI exposure.  Because diacetyl-HDA-Hb concentrations were not 
detectable and monoacetyl-HDA-Hb was only detected in one worker, further statistical investigation 
of these compounds was not feasible.  Using linear regression, we were able to demonstrate the utility 
of HDA-Hb adduct as a biomarker of cumulative HDI dermal or inhalation exposure.  The detection 
of HDA-Hb adducts in the majority of blood samples indicate that HDA-Hb adducts are sufficiently 
sensitive and specific as biomarker of cumulative exposure to HDI. 
   We observed ~10-fold higher total circulating amounts of HDA-Hb adducts (GM = 2.5 µg, GSD = 
2.1) relative to plasma HDA (GM = 0.21 µg, GSD = 2.9), after adjusting for plasma volume or blood 
volume
70
 and average male Hb concentration (16 g/dl), which is contrary to observations for other 
diamine adducts (e.g., plasma MDA > MDA-Hb)
19
.  This may be related to differences in the stability 
of metabolic intermediates, which could influence the yields of various protein adducts (albumin vs. 
Hb).  The bis-thiocarbamate intermediate of HDI, which can be easily transported into RBCs, is more 
stable compared to TDI or MDI
18
.  Therefore, the stability of this metabolic intermediate would allow 
greater opportunity for cellular uptake and subsequent Hb-adduct formation following further 
transformation. Another interesting point to consider is the involvement of different enzyme systems 
in the metabolism of primary aliphatic amines (e.g., HDA, monoacetyl-HDA) versus primary 
aromatic amines (e.g., MDA), which may be oxidized by cytochrome P450
80
.  The possible 
involvement of both an FAD-dependent enzyme system, which is involved in oxidation of basic 
aliphatic amines (e.g., HDA), and cytochrome P450-dependent system
20
 may explain these 
differences in the types and yields of various plasma and Hb adducts. 
   The time-dependent associations between plasma HDA or HDA-Hb and urine HDA concentration 
indicate long-term elimination kinetics among blood biomarkers.  The association between 
cumulative plasma HDA and urine HDA concentration was stronger compared to the same day 
plasma HDA concentration, indicating the breakdown and excretion of longer-term plasma protein 
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adducts.  The association between cumulative HDA-Hb adducts and urine HDA concentration was 
stronger than the same day HDA-Hb adduct concentration, indicating the breakdown of Hb upon 
death of the red blood cell (120 day lifespan) and subsequent excretion of HDA-Hb adducts.  The 
long-term elimination kinetics of these metabolites (HDA-Hb adducts and plasma HDA) may have 
important implications in HDI exposure monitoring and biological availability of these adducts for 
disease development. 
   The time-dependent associations between plasma HDA or HDA-Hb and HDI dermal, inhalation, or 
air exposure indicated the utilization of plasma HDA and HDA-Hb adducts as biomarkers of 
cumulative HDI exposure.  The inverse association between plasma HDA and HDI exposure may be 
partially attributed to the non-specificity of plasma HDA measures and indicate competing metabolic 
pathways.  The benefit of HDA-Hb or monoacetyl-HDA-Hb adduct analyses is obtaining measures of 
specific biomarkers that may be related to different exposure routes and metabolic pathways 
contributing to disease development.  Protein adducts may be formed via enzymatic-directed 
pathways, such as conjugation of metabolites to cysteine residues of glutathione by GST or oxidation 
of HDA or monoacetyl-HDA by FAD or cytochrome P450 systems.  Polymorphisms in GST have 
been suggested to play an important role in the inception of ill effects related to diisocyanate 
exposure
81
.  Therefore, individual differences in how diisocyanates are metabolized and the types of 
products formed may be important factors related to individual susceptibility for disease. 
   The inverse association between cumulative HDA-Hb adducts or plasma HDA and urine HDA 
concentration may be attributed to competing metabolic pathways leading to the formation of long-
lived protein adducts. HDA in acid-hydrolyzed urine and plasma (i.e., non-specific) may be partially 
derived from albumin adducts, and HDA in base-treated Hb (i.e., specific) is completely derived from 
Hb adducts.  The variable specificity of plasma HDA and HDA-Hb measures may also explain the 
poor association between the same day HDA-Hb adduct and plasma HDA concentrations.  Therefore, 
exposure or metabolism that favors albumin or Hb adduct formation (e.g., slow acetylators) would 
result in less acetylated-HDA metabolites (N-acetylation pathway) and, consequently, less urine 
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HDA.  Brorson and colleagues observed lower HDA amounts in acid-treated urine among slow 
acetylators receiving oral exposure to HDA compared with rapid acetylators
21
, supporting this 
hypothesis of competing metabolic pathways. The lack of detectable diacetyl-HDA-Hb and 
monoacetyl-HDA-Hb adducts also supports the presence of alternative metabolic pathways (e.g., 
oxidation of HDA) resulting in Hb adduct formation.  These findings for plasma HDA and HDA-Hb 
adducts may indicate long residence-time characteristics, which may be utilized in HDI exposure 
assessment. 
   There were several limitations in our estimates of HDI exposure through the inhalation route.  All 
15 workers wore a respirator during spray painting (83% wore half-face air purifying, 8% wore full-
face air purifying, and 8% wore supplied air) which would reduce exposure through the inhalation 
route.  However, inhalation exposure may occur due to improper fit and maintenance of respirators, 
particularly among workers wearing air-purifying respirators, and would contribute to the within- and 
between-worker variability in biomarker levels.  Because breathing-zone measures were taken outside 
of the respirator, we were unable to adjust for these various factors in our HDI inhalation exposure 
estimations.  Therefore, adjusting by the APF in estimating inhalation exposure may underestimate 
the workers’ true exposure if these issues were a concern.  However, the associations between blood 
biomarker concentrations and inhalation exposure estimates were stronger than associations with air 
exposure estimates indicating that adjusting for respirator use better reflects exposure through the 
inhalation route. 
   There were also several limitations in our estimates of HDI exposure through the dermal route.  The 
high percentage of non-detectable dermal exposure measures (60% of paint tasks) for HDI monomer 
using tape-stripping of the skin limited our ability in making strong conclusions about the dermal 
exposure route.  However, several workers did not wear gloves (13%) or coveralls (27%) and, thus, 
dermal exposure was a potential route for uptake of HDI.  Analytical methods to measure skin protein 
adducts from HDI exposure and secondary exposure to HDA, the hydrolysis product of HDI, may 
result in better estimates of dermal exposure.  Additionally, there was a strong, positive association 
87 
 
between HDI dermal and inhalation exposure (N = 35, r
2
 = 0.27, p = 0.0015).  Therefore, the issue of 
high collinearity between these exposure routes prevents drawing strong conclusions about the 
relative significance of either route on internal dose.  However, we demonstrated a strong, positive 
association between cumulative HDI dermal exposure and HDA-Hb adduct concentration, indicating 
the potential importance of dermal exposure among spray painters.  Whether exposure route (i.e., 
dermal vs. inhalation) or exposure type (HDI vs. HDA) has an impact on the type and yield of protein 
adducts formed requires further investigation.   
   Another source of the within-worker variability in plasma HDA or HDA-Hb concentrations may be 
the aging of PPE (e.g., coveralls, respirator filters) over long periods of use, which would lead to 
eventual breakthrough of the material.  Additionally, differences in exposure route (e.g., dermal vs. 
inhalation) or exposure type (e.g., HDI vs. HDA) would also contribute to both the within- and 
between-worker variability.  Other sources of the between-worker variability in biomarker 
concentrations may be related to genetic polymorphisms affecting enzymes regulating HDI 
metabolism (e.g., GST, NAT).  Future studies should investigate whether differences in exposure 
route, PPE use, and genetic factors play a role in predicting these biomarker levels.  Such information 
could be used to understand the relative importance of dermal and inhalation exposure, workplace 
covariates, and genetic factors on susceptibility for developing adverse health effects. 
 
4.7 Conclusions 
   We presented a method for quantifying HDA, monoacetyl-HDA, and diacetyl-HDA in Hb from 
HDI exposed individuals and demonstrated the utility of HDA-Hb adducts as biomarkers of exposure 
to HDI monomer.  The time-dependent associations between HDI dermal, inhalation, or air exposure 
and HDA-Hb adduct or plasma HDA concentrations demonstrate their utilization as biomarkers of 
cumulative HDI exposure.  The time-dependent associations between urine HDA and HDA-Hb or 
plasma HDA concentrations demonstrate long-term elimination kinetics among these biomarker 
types.  Monoacetyl-HDA and diacetyl-HDA hemoglobin adducts may have limited use as markers of 
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HDI exposure due to the low levels observed in this study population.  We demonstrated that HDA-
Hb adducts are sensitive and specific biomarkers of HDI monomer exposure.  Further 
characterization of urine and blood biomarkers resulting from HDI exposure may reveal important 
metabolic pathways contributing to individual susceptibility for disease. 
CHAPTER 5 
 
DISCUSSION AND CONCLUSIONS 
 
 
 
   In this dissertation, I have presented new methodologies for the identification and quantification of 
novel biomarkers related to HDI exposure and applied these methods to biological samples collected 
in the occupational setting (Chapters 2 – 4).   In Chapter 2, I presented a method that was developed 
and applied to quantify plasma HDA in a cohort of 46 workers occupationally exposed to HDI 
monomer and discussed how these measures were associated with HDI dermal and inhalation 
exposure and modified by personal and workplace covariates.  In Chapter 3, I presented a method that 
was developed and applied to quantify novel urine biomarkers (i.e., monoacetyl-HDA and diacetyl-
HDA) in three workers exposed to HDI monomer, as well as integrated currently proposed HDI 
metabolic pathways based on these measures and previously published metabolic pathways. In 
Chapter 4, I presented a method that was developed and applied to quantify hemoglobin adducts in a 
cohort of 15 workers occupationally exposed to HDI monomer and discussed how these measures 
were associated with other biomarkers (i.e., urine and plasma HDA), as well as cumulative dermal 
and inhalation exposure to HDI monomer.  In these chapters I provided important information on the 
significant determinants of blood biomarker concentrations related to HDI exposure and demonstrated 
the importance of integrating HDI exposure measures, workplace covariates, and urine HDA 
concentration with blood biomarker levels to further understand the exposure – dose relationship.   
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5.1 Biomarker analysis 
   Variable reaction conditions using acid or base hydrolysis were implemented prior to GC-MS 
analysis in the identification and quantification of HDI biomarkers in urine, plasma, or hemoglobin.  
Acid hydrolysis, while improving the analytical sensitivity of HDA analysis in urine and plasma, also 
prevents identifying the specific adducts comprising HDA (e.g., HDA vs. monoacetyl-HDA).  Base 
hydrolysis or no hydrolysis of urine allowed the identification and quantification of both monoacetyl-
HDA and diacetyl-HDA, respectively.  Base hydrolysis of hemoglobin also allowed the detection and 
quantification of HDA-Hb and monoacetyl-HDA-Hb adducts.  Using these different treatment 
conditions, various acetylated-HDA and HDA-proteins adducts were quantified and associated with 
HDI exposure levels.  While base hydrolysis or no hydrolysis resulted in improved analytical 
detection of specific biomarkers compared to acid hydrolysis, the overall sensitivity of the analysis is 
diminished; HDA detection in acid hydrolyzed urine may not necessarily yield detectable 
monoacetyl-HDA or diacetyl-HDA.  However, these specific biomarkers may be used to investigate 
inter-individual differences in HDI metabolism, which may be associated with enhanced risk for 
diisocyanate-induced asthma
16
.  These various biomarker concentrations may be modified by 
exposure route
56
 due to differences in absorption, distribution, metabolism and elimination (ADME) 
via skin vs. lungs, timing of urine or blood sample collection relative to exposure, and personal or 
workplace modifiers (e.g., PPE use).  Thus, factors related to ADME of HDI and biological 
availability of various metabolic intermediates may be relevant in asthma development. 
 
5.2 Metabolism of HDI 
   The identification of monoacetyl-HDA and diacetyl-HDA in base-hydrolyzed urine demonstrated, 
for the first time, the occurrence of N-acetylation pathway catalyzed by NAT enzymes among 
workers occupationally exposure to HDI monomer (Chapter 2).  The quantification of HDA-Hb and 
monoacetyl-HDA-Hb adducts also indicated the presence of N-oxidation pathway, which may be 
catalyzed by CYP450 isoforms, an FAD-dependent enzyme system
20
, and/or GST enzymes.  The 
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presence of HDA in the plasma of workers exposed to HDI monomer also indicates the possible 
formation of HDA albumin adducts, which may be formed via similar pathways as HDA-Hb adducts.  
The inter-individual variability in protein adduct formation may be associated with enhanced risk of 
developing occupational asthma.  Polymorphisms in GST and NAT genes have been suggested to 
play an important role in the inception of ill effects related to diisocyanate exposure by altering GST 
and NAT enzyme activities involved in HDI metabolism.  The lower urine HDA amounts among 
slow acetylators receiving oral exposure to HDA compared with fast acetylators also indicates 
variability in the type and yield of metabolites based on individual phenotype.  Therefore, personal 
and workplace factors modifying HDI exposure as well as inter-individual differences in gene 
polymorphisms affecting enzyme activity involved in HDI metabolism may be factors contributing to 
the enhanced risk of developing occupational asthma. 
 
5.3 Blood HDA vs. HDI exposure 
   Time-dependent associations between plasma HDA, HDA-Hb, or urine HDA concentrations with 
HDI dermal or air exposure (i.e., unadjusted for respirator type) are summarized in Table 5.1, which 
highlights (in red) the strongest associations between the correlated variables.  These time-dependent 
associations between plasma HDA and dermal or air exposure to HDI monomer was observed in our 
cohort of 46 workers (Chapter 2).  The association between plasma HDA and dermal or air exposure 
to HDI occurring in the previous 0.5 – 2 months (i.e., 1 – 3 albumin half-lives) was stronger than with 
the same day HDI exposure.  Because albumin has a half-life of 19 days, these findings indicate the 
presence of HDA-albumin adducts which may persist, at least, over the albumin half-life.  There was 
also a strong association between HDA-Hb and cumulative dermal, inhalation, or air exposure to 
HDI, occurring within 4 months prior to blood collection, in our cohort of 15 workers (Chapter 4).  
This time-frame corresponds to the lifespan of Hb (120 days) at which time the RBC, and Hb adducts 
contained within, are broken down.  The time-dependent associations between plasma HDA or HDA-
Hb concentration and HDI exposure, which are summarized in Table 5.1, demonstrate their potential 
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use as indicators of past HDI exposure.  In addition, the advantage of HDA-Hb or monoacetyl-HDA-
Hb adduct analyses is obtaining measures of specific biomarkers that may be related to different 
exposure routes (dermal vs. inhalation), biological availability, and inter-individual differences in 
HDI metabolism associated with enhanced risk for asthma development. 
 
Table 5.1 Time-dependent associations between log-transformed same day or previous HDI monomer exposure (air or dermal) with HDA 
biomarker concentration in plasma (ng/ml), hemoglobin (ng/g Hb), and urine (ng/ml) and correlations between same day or 
previous blood (plasma and hemoglobin) and urine HDA biomarker concentrations. 
        Same day
c 0.5 – 2 monthsd 0.5 – 4 monthse 
Association (Bio)marker
a n N r2 p-value Sample range r2 p-value Sample range r2 p-value Sample range 
Air:    Dermalf Dermal HDI 48 278 0.40 <0.001 ≤0.01 – 179 µg/mm3 NA NA NA NA NA NA 
Plasma:     Hb HDA 46 108 0.039 0.38 ≤1.2 – 37.2 ng/g NA NA NA NA NA NA 
Air:                  
Plasma Total HDA 46 108 0.058 0.013 ≤0.02 – 0.90 µg/l 0.33 0.0014 ≤0.02 – 0.14 µg/l 0.14 0.061 ≤0.02–0.71 µg/l 
Hb HDA
b 15 35 0.085 0.10 ≤1.2 – 37.2 ng/g 0.15 0.12 ≤1.2 – 37.2 ng/g 0.34 0.008 ≤1.2–7.6 ng/g 
Urine Total HDA
b 15 35 0.018 0.45 ≤0.03 – 66 µg/l 0.11 0.44 ≤0.03 – 0.80 µg/l 0.007 0.97 ≤0.03–4.0 µg/l 
Dermal:                  
Plasma Total HDA 46 108 0.063 0.012 ≤0.02 – 0.90 µg/l 0.13 0.053 ≤0.02 – 0.14 µg/l 0.086 0.15 ≤0.02–0.71 µg/l 
Hb HDAb 15 35 0.10 0.071 ≤1.2 – 37.2 ng/g 0.20 0.38 ≤1.2 – 37.2 ng/g 0.13 0.10 ≤1.2–7.6 ng/g 
Urine Total HDA
b 15 35 0.024 0.51 ≤0.03 – 66 µg/l 0.19 0.33 ≤0.03 – 0.80 µg/l 0.021 0.58 ≤0.03–4.0 µg/l 
Plasma:                  
Hb HDA
b 15 35 0.039 0.38 ≤0.02 – 0.90 µg/l 0.27 0.26 ≤1.2 – 37.2 ng/g 0.096 0.33 ≤1.2–7.6 ng/g 
Urine Total HDA
b 15 35 0.30 0.001 ≤0.03 – 25.9 µg/l 0.50 0.007 ≤0.03 – 0.80 µg/l 0.26 0.017 ≤0.03–4.0 µg/l 
Hb:         Urine Total HDA
b 15 35 0.015 0.49 ≤0.03 – 25.9 µg/l 0.016 0.69 ≤0.03 – 0.80 µg/l 0.21 0.065 ≤0.03–4.0 µg/l 
Air = Σtask(breathing-zone concentration × paint time) = µg/m
3
 × min; Dermal = Σtask (skin concentration) = µg/mm
3
; Hb = hemoglobin; NA = not 
applicable; LOD = limit of detection;    n = number of workers; N = number of samples  
a.
 Exposure or biomarker variable analyzed; total HDA derived from acid-hydrolyzed urine. 
b.
 Random subset of workers from 46 total workers used in regression analysis; post-exposure urine samples used in regression analysis. 
c. 
HDI exposure (BZ, dermal), urine HDA, plasma HDA, or HDA-Hb measured on the same day.  Strongest association with dermal HDI (bolded). 
d. 
HDI exposure (BZ, dermal), plasma HDA, or HDA-Hb measured in the previous 0.5 – 2 months.  Strongest association with Hb (red) or plasma (blue). 
e. 
HDI exposure (BZ, dermal), plasma HDA, or HDA-Hb measured in the previous 0.5 – 4 months.  Strongest association with Hb (red) or plasma (blue). 
f.
 Reported in previous publication (Fent et al., 2009)
41
. 
 
9
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5.4 Blood HDA vs. urine HDA 
   Time-dependent associations between plasma HDA or HDA-Hb and urine HDA concentration were 
observed in our cohort of 15 workers and are summarized in Table 5.1.  The strongest association 
between plasma HDA and total urine HDA occurred using urine collected 0.5 – 2 months following 
blood collection, indicating the breakdown and excretion of long-term albumin adducts (Table 5.1).  
The strongest association between HDA-Hb and total urine HDA occurred using urine collected 0.5 – 
4 months following blood collection, demonstrating the breakdown and excretion and longer-lived 
HDA-Hb adducts.  The narrower excretion time-frame associating plasma and urine HDA indicates a 
more rapid turnover of albumin and elimination of HDA-albumin adducts compared with HDA-Hb 
adducts.  A strong association between cumulative HDA-Hb and pre-shift, post-shift, or total urine 
HDA concentrations was observed (Chapter 4), indicating long-term elimination of these protein 
adducts.  These time-dependent associations between plasma HDA or HDA-Hb and urine HDA may 
have important implications in HDI exposure monitoring and in the biological availability of these 
adducts in development of adverse health effects.  The strong, inverse association in HDA-Hb and 
urine HDA concentration may also indicate the presence of competing metabolic pathways (e.g., N-
acetylation vs. N-oxidation) involved in forming these various biomarkers.  Inverse association 
between an administered oral HDA dose and urine HDA among slow acetylators (i.e., greater protein 
adduct formation) have been previously observed and attributed to the relative contribution of these 
competing metabolic pathways
21
. 
 
5.5 Workplace covariates 
   Workplace and personal covariates (e.g., coverall use, booth type) may affect biomarker levels by 
modifying the received HDI exposure dose through inhalation and dermal routes.  From analysis of 
variance and mixed models of measured biomarker levels, the most significant covariates affecting 
total plasma HDA dose (after adjusting for plasma volume) were coverall use and booth type 
(Chapters 2).  The various significant or non-significant trends in plasma HDA, HDA-Hb 
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concentrations, HDI air or HDI dermal exposure stratified by these workplace covariates among the 
cohort of 15 workers are summarized in Table 5.2.  Each covariate (i.e., coverall use or downdraft 
booth) was evaluated by holding one variable constant (i.e., group) and observing the trend in 
exposure or biomarker levels from non-use (0) to use (1) of the other variable.  Among workers 
grouped by coverall use (Table 5.2), HDI exposure (dermal and/or air) and HDA-Hb concentration 
varied significantly between downdraft booth users compared to non-users indicating that use of the 
downdraft booth type decreases both air and dermal exposures, which in turn decreases HDA-Hb 
concentration.  Interestingly, coverall use was inversely associated with HDA-Hb concentration; 
coverall users had moderately higher HDA-Hb concentration compared to non-coveralls users.  This 
may be attributed to the significantly higher HDI air exposure levels among coverall users (p < 0.05) 
due to longer exposure times and higher HDI paint concentration relative to non-coverall users.  Thus, 
higher air exposure may have contributed to enhanced HDI inhalation exposure among coverall users, 
resulting in higher HDA-Hb concentration.  Whether these observations indicate exposure-route 
specific biomarkers, which may have important applications in HDI exposure assessment, need to be 
further investigated.  Other sources of variability in these levels, which were not analyzed in these 
studies, may include genetic differences in HDI metabolism that can affect the types and yields of 
different blood biomarkers and the proportion of biomarker concentration attributed to specific 
exposure routes (dermal vs. inhalation). 
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Table 5.2 Summary of blood biomarker and HDI monomer exposure trends stratified by 
workplace covariates among 15 workers. 
Covariate 
 Biomarker
a
 Exposure
a
 
N 
Plasma HDA 
(ng/l) 
 HDI Air 
HDI Dermal 
(ng/mm
3
) 
HDA-Hb 
(ng/g Hb) 
(µg/m
3
 × 
min) 
Group  Comparison    GM  trend GM  trend GM  trend GM   trend 
Downdraft 
booth
b
 Coveralls    
  
    
  
  
yes 
yes 17 39 
  
2.7   79 
  
54  
no 6 153 2.0 16 89 
Coveralls 
Downdraft 
booth    
  
 
  
 
  
 
 
yes 
yes 17 39 
  
2.7 
  
79 
  
54 
 no 6 71 5.5 210 260 
                 
no 
yes 6 153   2.0   16   89 
 no 6 73 3.3 85 980 
N = number of samples; GM = geometric mean 
a. Colored arrows (red or blue) indicate significant difference (p ≤ 0.10) in HDA biomarker 
concentration or HDI exposure stratified by covariate (no = 0; yes = 1) using Tukey-Kramer 
multiple comparisons testing; significant difference stratified by covariate and similar directional 
trend between HDA-Hb and HDI exposure (red) or plasma HDA and HDI exposure (blue); black 
arrows indicate non-significant difference (p > 0.10); direction of arrow indicates whether 
association is increased (up arrow) or decreased (down arrow) within each comparison from 0 to 1. 
b. No significant differences (p > 0.10) in biomarker or exposure concentrations stratified by coverall 
use among workers not using a downdraft booth. 
 
5.6 Limitations and suggestions for future research 
   There were several limitations in these studies involving both plasma HDA and inhalation and 
dermal HDI exposure estimates (Chapter 2 and 4).  Because HDA analysis in plasma involved acid 
hydrolysis, information on the specific constituents of HDA was masked (e.g., HDA vs. monoacetyl-
HDA, adduct vs. unbound).  Additionally, estimates of inhalation exposure adjusted or unadjusted for 
respirator type (Chapter 2 and 4) used breathing-zone concentrations measured outside of the 
respirator and did not take into account improper fit and maintenance of respirators, which may 
increase the potential for inhalation exposure.  Therefore, adjusted inhalation exposure by respirator 
type would have underestimated the true inhalation exposure while the unadjusted values most likely 
overestimated inhalation exposure.  Because the majority (65%) of task-based HDI dermal exposure 
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measurements was less than the LOD
41
, the associations between biomarker levels and HDI dermal 
exposure must be interpreted with caution.  These limitations in inhalation and dermal exposure 
measurements also prevent making strong conclusions about the major routes of exposure or the 
proportion of internal dose attributed to dermal or inhalation exposure routes.   
   Further work investigating the dermal uptake kinetics of HDI monomer and the formation of skin-
protein adducts with HDI (e.g., keratin adducts) may help improve dermal exposure assessment 
strategies for future studies and better understand the contribution of dermal exposure route on 
internal dose levels.  Based on our preliminary analysis of monoacetyl-HDA and diacetyl-HDA in 
urine from 3 exposed workers (Chapter 3), specific biomarkers related to N-acetyl metabolism may be 
investigated further in this study population.  These biomarkers may be associated with individual 
differences in enzyme-directed metabolism (e.g., NAT, GST) resulting from gene associated single 
nucleotide polymorphisms (SNPs).  Candidate SNPs may be selected and integrated with the 
significant HDI exposure variables and workplace covariates identified in these studies to improve 
predictive models for biomarker concentrations.  This would not only help mitigate exposures in the 
workplace by advising optimum protection controls but also identify susceptibility factors (e.g., slow 
vs. fast acetylation) that may enhance risk for development of occupational asthma. 
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